

Chemotherapy agents - Alkylating agents (including Platinum drugs): All cancers

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	569	2.4	220	0.9	865	3.7	801	3.4	59	0.3	2119	9.1	10389	44.6
	Age at baseline	<18	5290	94	1.8	43	0.8	302	5.7	172	3.3	3	0.1	547	10.4	2472	47.1
		18-19	1964	38	1.9	16	0.8	114	5.8	56	2.9	.	.	157	8.1	867	44.6
		20-24	5470	108	2.0	46	0.8	219	4.0	177	3.3	12	0.2	557	10.3	2375	43.8
		25-29	5110	164	3.2	56	1.1	150	3.0	220	4.3	10	0.2	444	8.8	2237	44.3
		30-34	3523	97	2.8	35	1.0	60	1.7	130	3.7	13	0.4	282	8.1	1579	45.5
		35+	2201	68	3.1	24	1.1	20	0.9	46	2.1	21	1.0	132	6.1	859	39.7
	Years since diagnosis	5-9	2383	88	3.7	20	0.8	98	4.2	131	5.6	11	0.5	361	15.3	1159	49.3
		10-14	7680	161	2.1	63	0.8	316	4.1	271	3.6	9	0.1	708	9.3	3651	48.0
		15-19	7552	163	2.2	88	1.2	345	4.6	223	3.0	14	0.2	594	7.9	3210	43.0
		20+	5943	157	2.7	49	0.8	106	1.8	176	3.0	25	0.4	456	7.7	2369	40.4
	Age at diagnosis	<1	1778	16	0.9	24	1.4	131	7.4	29	1.6	.	.	215	12.2	790	44.9
		1-4	7584	141	1.9	58	0.8	352	4.7	172	2.3	6	0.1	625	8.3	3186	42.4
		5-9	5282	123	2.3	38	0.7	186	3.5	265	5.1	8	0.2	426	8.1	2297	43.9
		10-14	4993	155	3.1	59	1.2	124	2.5	205	4.1	15	0.3	507	10.2	2427	49.2
		15-20	3921	134	3.5	41	1.1	72	1.9	130	3.4	30	0.8	346	9.0	1689	43.8
Males	All cases		12463	338	2.7	112	0.9	486	3.9	489	4.0	26	0.2	1162	9.4	5743	46.6
	Age at baseline	<18	2841	50	1.8	15	0.5	175	6.2	110	3.9	3	0.1	312	11.1	1392	49.5
		18-19	1014	26	2.6	10	1.0	56	5.6	33	3.3	.	.	80	7.9	473	47.0
		20-24	2840	60	2.1	25	0.9	122	4.3	111	3.9	10	0.4	299	10.6	1271	45.2
		25-29	2800	109	3.9	30	1.1	92	3.3	142	5.1	2	0.1	254	9.2	1272	46.0
		30-34	1856	63	3.4	20	1.1	29	1.6	68	3.7	4	0.2	144	7.9	873	47.7
		35+	1112	30	2.7	12	1.1	12	1.1	25	2.3	7	0.6	73	6.7	462	42.2
	Years since diagnosis	5-9	1326	51	3.9	7	0.5	50	3.8	79	6.0	9	0.7	195	14.9	671	51.4
		10-14	4084	97	2.4	32	0.8	181	4.5	174	4.3	4	0.1	399	9.8	2021	49.9
		15-19	3918	100	2.6	47	1.2	192	5.0	137	3.5	5	0.1	327	8.4	1749	45.2
		20+	3135	90	2.9	26	0.8	63	2.0	99	3.2	8	0.3	241	7.8	1302	42.0
	Age at diagnosis	<1	901	7	0.8	10	1.1	75	8.4	19	2.1	.	.	107	12.0	401	45.1
		1-4	3934	79	2.0	32	0.8	194	5.0	107	2.7	5	0.1	347	8.9	1750	44.9
		5-9	2955	85	2.9	19	0.6	113	3.9	173	5.9	1	0.0	255	8.7	1352	46.3
		10-14	2603	96	3.7	24	0.9	65	2.5	110	4.3	8	0.3	250	9.7	1297	50.3
		15-20	2070	71	3.5	27	1.3	39	1.9	80	3.9	12	0.6	203	10.0	943	46.4
Females	All cases		11095	231	2.1	108	1.0	379	3.4	312	2.8	33	0.3	957	8.7	4646	42.3
	Age at baseline	<18	2449	44	1.8	28	1.1	127	5.2	62	2.5	.	.	235	9.6	1080	44.4
		18-19	950	12	1.3	6	0.6	58	6.2	23	2.4	.	.	77	8.2	394	41.9
		20-24	2630	48	1.8	21	0.8	97	3.7	66	2.5	2	0.1	258	9.9	1104	42.4
		25-29	2310	55	2.4	26	1.1	58	2.5	78	3.4	8	0.3	190	8.3	965	42.3
		30-34	1667	34	2.1	15	0.9	31	1.9	62	3.8	9	0.5	138	8.4	706	42.9
		35+	1089	38	3.5	12	1.1	8	0.7	21	2.0	14	1.3	59	5.5	397	37.1
	Years since diagnosis	5-9	1057	37	3.5	13	1.2	48	4.6	52	5.0	2	0.2	166	15.8	488	46.6
		10-14	3596	64	1.8	31	0.9	135	3.8	97	2.7	5	0.1	309	8.7	1630	45.8
		15-19	3634	63	1.7	41	1.1	153	4.2	86	2.4	9	0.2	267	7.4	1461	40.6
		20+	2808	67	2.4	23	0.8	43	1.5	77	2.8	17	0.6	215	7.7	1067	38.5
	Age at diagnosis	<1	877	9	1.0	14	1.6	56	6.4	10	1.1	.	.	108	12.4	389	44.8
		1-4	3650	62	1.7	26	0.7	158	4.4	65	1.8	1	0.0	278	7.7	1436	39.7
		5-9	2327	38	1.6	19	0.8	73	3.2	92	4.0	7	0.3	171	7.4	945	40.9
		10-14	2390	59	2.5	35	1.5	59	2.5	95	4.0	7	0.3	257	10.9	1130	48.0
		15-20	1851	63	3.5	14	0.8	33	1.8	50	2.7	18	1.0	143	7.8	746	41.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): All cancers

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	918	3.9	1274	5.5	282	1.2	1083	4.6	2088	8.9	185	0.8	32	0.1
	Age at baseline	<18	5290	160	3.0	213	4.0	98	1.9	80	1.5	156	3.0	41	0.8	22	0.4
		18-19	1964	40	2.1	89	4.6	17	0.9	32	1.6	63	3.2	18	0.9	4	0.2
		20-24	5470	174	3.2	334	6.2	54	1.0	164	3.0	307	5.7	41	0.8	1	0.0
		25-29	5110	187	3.7	313	6.2	36	0.7	250	4.9	566	11.2	31	0.6	5	0.1
		30-34	3523	197	5.7	229	6.6	42	1.2	285	8.2	573	16.5	30	0.9	.	.
		35+	2201	160	7.4	96	4.4	35	1.6	272	12.6	423	19.6	24	1.1	.	.
	Years since diagnosis	5-9	2383	145	6.2	148	6.3	44	1.9	121	5.1	214	9.1	24	1.0	9	0.4
		10-14	7680	296	3.9	396	5.2	101	1.3	270	3.5	680	8.9	48	0.6	20	0.3
		15-19	7552	225	3.0	499	6.7	81	1.1	354	4.7	638	8.5	79	1.1	3	0.0
		20+	5943	252	4.3	231	3.9	56	1.0	338	5.7	556	9.5	34	0.6	.	.
	Age at diagnosis	<1	1778	89	5.0	56	3.2	21	1.2	30	1.7	41	2.3	9	0.5	7	0.4
		1-4	7584	134	1.8	321	4.3	104	1.4	97	1.3	159	2.1	68	0.9	14	0.2
		5-9	5282	129	2.5	275	5.2	49	0.9	150	2.9	334	6.4	29	0.6	5	0.1
		10-14	4993	256	5.2	353	7.1	41	0.8	400	8.1	771	15.6	23	0.5	3	0.1
		15-20	3921	310	8.0	269	7.0	67	1.7	406	10.5	783	20.3	56	1.4	3	0.1
Males	All cases		12463	482	3.9	704	5.7	138	1.1	590	4.8	1094	8.9	102	0.8	17	0.1
	Age at baseline	<18	2841	88	3.1	135	4.8	50	1.8	44	1.6	102	3.6	21	0.7	12	0.4
		18-19	1014	27	2.7	45	4.5	6	0.6	23	2.3	38	3.8	8	0.8	1	0.1
		20-24	2840	96	3.4	176	6.3	27	1.0	100	3.6	182	6.5	21	0.7	1	0.0
		25-29	2800	95	3.4	177	6.4	18	0.6	149	5.4	311	11.2	21	0.8	3	0.1
		30-34	1856	108	5.9	121	6.6	19	1.0	151	8.2	278	15.2	19	1.0	.	.
		35+	1112	68	6.2	50	4.6	18	1.6	123	11.2	183	16.7	12	1.1	.	.
	Years since diagnosis	5-9	1326	76	5.8	86	6.5	21	1.6	73	5.6	125	9.5	13	1.0	5	0.4
		10-14	4084	152	3.7	224	5.5	52	1.3	144	3.6	355	8.8	26	0.6	9	0.2
		15-19	3918	122	3.1	271	7.0	41	1.1	198	5.1	339	8.8	42	1.1	3	0.1
		20+	3135	132	4.2	123	4.0	24	0.8	175	5.6	275	8.9	21	0.7	.	.
	Age at diagnosis	<1	901	43	4.8	33	3.7	9	1.0	12	1.3	22	2.5	4	0.4	5	0.6
		1-4	3934	75	1.9	181	4.6	51	1.3	59	1.5	94	2.4	36	0.9	7	0.2
		5-9	2955	90	3.1	159	5.4	22	0.8	106	3.6	231	7.9	15	0.5	2	0.1
		10-14	2603	134	5.2	187	7.2	20	0.8	216	8.4	377	14.6	15	0.6	1	0.0
		15-20	2070	140	6.9	144	7.1	36	1.8	197	9.7	370	18.2	32	1.6	2	0.1
Females	All cases		11095	436	4.0	570	5.2	144	1.3	493	4.5	994	9.0	83	0.8	15	0.1
	Age at baseline	<18	2449	72	2.9	78	3.2	48	2.0	36	1.5	54	2.2	20	0.8	10	0.4
		18-19	950	13	1.4	44	4.7	11	1.2	9	1.0	25	2.7	10	1.1	3	0.3
		20-24	2630	78	3.0	158	6.0	27	1.0	64	2.4	125	4.8	20	0.8	.	.
		25-29	2310	92	4.0	136	5.9	18	0.8	101	4.4	255	11.1	10	0.4	2	0.1
		30-34	1667	89	5.4	108	6.5	23	1.4	134	8.1	295	17.9	11	0.7	.	.
		35+	1089	92	8.6	46	4.3	17	1.6	149	13.9	240	22.5	12	1.1	.	.
	Years since diagnosis	5-9	1057	69	6.6	62	5.9	23	2.2	48	4.6	89	8.5	11	1.0	4	0.4
		10-14	3596	144	4.0	172	4.8	49	1.4	126	3.5	325	9.1	22	0.6	11	0.3
		15-19	3634	103	2.9	228	6.3	40	1.1	156	4.3	299	8.3	37	1.0	.	.
		20+	2808	120	4.3	108	3.9	32	1.1	163	5.9	281	10.1	13	0.5	.	.
	Age at diagnosis	<1	877	46	5.3	23	2.6	12	1.4	18	2.1	19	2.2	5	0.6	2	0.2
		1-4	3650	59	1.6	140	3.9	53	1.5	38	1.0	65	1.8	32	0.9	7	0.2
		5-9	2327	39	1.7	116	5.0	27	1.2	44	1.9	103	4.4	14	0.6	3	0.1
		10-14	2390	122	5.1	166	7.0	21	0.9	184	7.8	394	16.7	8	0.3	2	0.1
		15-20	1851	170	9.4	125	6.9	31	1.7	209	11.5	413	22.7	24	1.3	1	0.1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	177	2.5	192	2.7	4	0.1	13	0.2	.	.	7	0.1	3845	53.6
	Age at baseline	<18	2096	48	2.3	39	1.9	2	0.1	8	0.4	.	.	6	0.3	1207	58.1
		18-19	769	11	1.4	13	1.7	.	.	3	0.4	387	50.7
		20-24	1788	27	1.5	36	2.0	1	0.1	1	0.1	853	48.2
		25-29	1459	58	4.0	50	3.5	1	0.1	765	52.9
		30-34	761	18	2.4	32	4.3	.	.	1	0.1	410	55.2
		35+	372	15	4.1	22	6.0	1	0.3	223	60.6
	Years since diagnosis	5-9	904	29	3.2	14	1.6	.	.	1	0.1	.	.	3	0.3	506	56.7
		10-14	2445	52	2.1	56	2.3	1	0.0	10	0.4	.	.	3	0.1	1481	61.1
		15-19	2236	36	1.6	75	3.4	3	0.1	2	0.1	.	.	1	0.0	1076	48.6
		20+	1660	60	3.6	47	2.9	782	47.7
	Age at diagnosis	<1	232	4	1.7	24	10.4	2	0.9	1	0.4	147	64.5
		1-4	3421	79	2.3	51	1.5	1	0.0	6	0.2	.	.	5	0.1	1670	49.2
		5-9	1754	35	2.0	30	1.7	.	.	4	0.2	.	.	1	0.1	867	50.0
		10-14	1203	33	2.8	50	4.2	.	.	2	0.2	.	.	1	0.1	772	64.8
		15-20	635	26	4.2	37	5.9	1	0.2	389	62.5
Males	All cases		3827	100	2.6	95	2.5	.	.	6	0.2	.	.	5	0.1	2084	55.1
	Age at baseline	<18	1136	25	2.2	12	1.1	.	.	4	0.4	.	.	4	0.4	660	58.7
		18-19	411	7	1.7	8	2.0	.	.	2	0.5	209	51.1
		20-24	891	12	1.4	19	2.1	435	49.2
		25-29	783	38	4.9	25	3.2	1	0.1	428	55.4
		30-34	397	13	3.4	20	5.2	227	58.8
		35+	209	5	2.4	11	5.3	125	60.4
	Years since diagnosis	5-9	510	16	3.2	3	0.6	.	.	1	0.2	.	.	2	0.4	289	57.3
		10-14	1301	30	2.3	28	2.2	.	.	5	0.4	.	.	2	0.2	793	61.5
		15-19	1136	20	1.8	39	3.5	1	0.1	574	51.2
		20+	880	34	3.9	25	2.9	428	49.2
	Age at diagnosis	<1	110	2	1.9	10	9.3	72	67.3
		1-4	1809	40	2.2	27	1.5	.	.	3	0.2	.	.	3	0.2	905	50.4
		5-9	935	27	2.9	13	1.4	.	.	3	0.3	.	.	1	0.1	479	52.0
		10-14	588	18	3.1	20	3.4	1	0.2	392	67.2
		15-20	385	13	3.4	25	6.6	236	62.6
Females	All cases		3418	77	2.3	97	2.9	4	0.1	7	0.2	.	.	2	0.1	1761	52.0
	Age at baseline	<18	960	23	2.4	27	2.8	2	0.2	4	0.4	.	.	2	0.2	547	57.3
		18-19	358	4	1.1	5	1.4	.	.	1	0.3	178	50.3
		20-24	897	15	1.7	17	1.9	1	0.1	1	0.1	418	47.2
		25-29	676	20	3.0	25	3.7	337	50.1
		30-34	364	5	1.4	12	3.3	.	.	1	0.3	183	51.3
		35+	163	10	6.2	11	6.9	1	0.6	98	60.9
	Years since diagnosis	5-9	394	13	3.3	11	2.8	1	0.3	217	55.8
		10-14	1144	22	1.9	28	2.5	1	0.1	5	0.4	.	.	1	0.1	688	60.8
		15-19	1100	16	1.5	36	3.3	3	0.3	2	0.2	502	45.8
		20+	780	26	3.4	22	2.8	354	46.1
	Age at diagnosis	<1	122	2	1.6	14	11.5	2	1.6	1	0.8	75	62.0
		1-4	1612	39	2.4	24	1.5	1	0.1	3	0.2	.	.	2	0.1	765	47.9
		5-9	819	8	1.0	17	2.1	.	.	1	0.1	388	47.8
		10-14	615	15	2.5	30	4.9	.	.	2	0.3	380	62.5
		15-20	250	13	5.3	12	4.9	1	0.4	153	62.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	2	0.0	49	0.7	13	0.2	7	0.1	2	0.0	27	0.4	.	.
	Age at baseline	<18	2096	.	.	6	0.3	4	0.2	1	0.0	.	.	5	0.2	.	.
		18-19	769	.	.	9	1.2	3	0.4	1	0.1	.	.	2	0.3	.	.
		20-24	1788	2	0.1	15	0.8	3	0.2	.	.	1	0.1	5	0.3	.	.
		25-29	1459	.	.	11	0.8	1	0.1	4	0.3	.	.	7	0.5	.	.
		30-34	761	.	.	7	0.9	2	0.3	1	0.1	.	.	2	0.3	.	.
		35+	372	.	.	1	0.3	1	0.3	6	1.6	.	.
	Years since diagnosis	5-9	904	.	.	5	0.6	2	0.2	1	0.1	.	.	3	0.3	.	.
		10-14	2445	.	.	13	0.5	4	0.2	2	0.1	.	.	5	0.2	.	.
		15-19	2236	1	0.0	20	0.9	7	0.3	1	0.0	1	0.0	12	0.5	.	.
		20+	1660	1	0.1	11	0.7	.	.	3	0.2	1	0.1	7	0.4	.	.
	Age at diagnosis	<1	232	.	.	1	0.4	2	0.9	.	.	1	0.4	2	0.9	.	.
		1-4	3421	1	0.0	22	0.6	4	0.1	1	0.0	.	.	10	0.3	.	.
		5-9	1754	1	0.1	13	0.7	3	0.2	4	0.2	.	.	5	0.3	.	.
		10-14	1203	.	.	10	0.8	1	0.1	2	0.2	.	.	1	0.1	.	.
		15-20	635	.	.	3	0.5	3	0.5	.	.	1	0.2	9	1.4	.	.
Males	All cases		3827	.	.	41	1.1	5	0.1	5	0.1	.	.	13	0.3	.	.
	Age at baseline	<18	1136	.	.	4	0.4	1	0.1	1	0.1	.	.	2	0.2	.	.
		18-19	411	.	.	8	2.0	.	.	1	0.2	.	.	1	0.2	.	.
		20-24	891	.	.	14	1.6	2	0.2	2	0.2	.	.
		25-29	783	.	.	9	1.2	1	0.1	2	0.3	.	.	2	0.3	.	.
		30-34	397	.	.	5	1.3	1	0.3	1	0.3	.	.	2	0.5	.	.
		35+	209	.	.	1	0.5	4	1.9	.	.
	Years since diagnosis	5-9	510	.	.	5	1.0	2	0.4	1	0.2	.	.	1	0.2	.	.
		10-14	1301	.	.	10	0.8	.	.	2	0.2	.	.	3	0.2	.	.
		15-19	1136	.	.	17	1.5	3	0.3	6	0.5	.	.
		20+	880	.	.	9	1.0	.	.	2	0.2	.	.	3	0.3	.	.
	Age at diagnosis	<1	110	.	.	1	0.9	1	0.9	.	.
		1-4	1809	.	.	17	0.9	1	0.1	1	0.1	.	.	4	0.2	.	.
		5-9	935	.	.	12	1.3	1	0.1	2	0.2	.	.	1	0.1	.	.
		10-14	588	.	.	8	1.4	1	0.2	2	0.3	.	.	1	0.2	.	.
		15-20	385	.	.	3	0.8	2	0.5	6	1.6	.	.
Females	All cases		3418	2	0.1	8	0.2	8	0.2	2	0.1	2	0.1	14	0.4	.	.
	Age at baseline	<18	960	.	.	2	0.2	3	0.3	3	0.3	.	.
		18-19	358	.	.	1	0.3	3	0.8	1	0.3	.	.
		20-24	897	2	0.2	1	0.1	1	0.1	.	.	1	0.1	3	0.3	.	.
		25-29	676	.	.	2	0.3	.	.	2	0.3	.	.	5	0.7	.	.
		30-34	364	.	.	2	0.6	1	0.3
		35+	163	1	0.6	2	1.2	.	.
	Years since diagnosis	5-9	394	2	0.5	.	.
		10-14	1144	.	.	3	0.3	4	0.4	2	0.2	.	.
		15-19	1100	1	0.1	3	0.3	4	0.4	1	0.1	1	0.1	6	0.5	.	.
		20+	780	1	0.1	2	0.3	.	.	1	0.1	1	0.1	4	0.5	.	.
	Age at diagnosis	<1	122	2	1.6	.	.	1	0.8	1	0.8	.	.
		1-4	1612	1	0.1	5	0.3	3	0.2	6	0.4	.	.
		5-9	819	1	0.1	1	0.1	2	0.2	2	0.2	.	.	4	0.5	.	.
		10-14	615	.	.	2	0.3
		15-20	250	1	0.4	.	.	1	0.4	3	1.2	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): ALL

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	138	2.3	13	0.2	1	0.0	12	0.2	.	.	3	0.0	3176	52.9
	Age at baseline	<18	1812	34	1.9	4	0.2	1	0.1	7	0.4	.	.	2	0.1	1039	57.8
		18-19	666	8	1.2	1	0.2	.	.	3	0.5	330	49.9
		20-24	1524	20	1.3	2	0.1	.	.	1	0.1	711	47.1
		25-29	1207	50	4.2	2	0.2	1	0.1	612	51.1
		30-34	590	13	2.2	3	0.5	.	.	1	0.2	312	54.2
		35+	268	13	4.9	1	0.4	172	64.9
	Years since diagnosis	5-9	777	26	3.4	2	0.3	.	.	1	0.1	.	.	1	0.1	432	56.3
		10-14	2049	36	1.8	4	0.2	.	.	10	0.5	.	.	1	0.0	1257	61.9
		15-19	1847	25	1.4	4	0.2	1	0.1	1	0.1	.	.	1	0.1	853	46.6
		20+	1394	51	3.7	3	0.2	634	46.1
	Age at diagnosis	<1	127	2	1.6	3	2.4	1	0.8	1	0.8	81	64.8
		1-4	3030	57	1.9	3	0.1	.	.	5	0.2	.	.	1	0.0	1453	48.4
		5-9	1537	33	2.2	2	0.1	.	.	4	0.3	.	.	1	0.1	746	49.1
		10-14	940	26	2.8	3	0.3	.	.	2	0.2	.	.	1	0.1	612	65.5
		15-20	433	20	4.7	2	0.5	284	67.5
Males	All cases		3231	84	2.6	5	0.2	.	.	6	0.2	.	.	2	0.1	1749	54.7
	Age at baseline	<18	982	20	2.0	1	0.1	.	.	4	0.4	.	.	1	0.1	570	58.6
		18-19	359	6	1.7	1	0.3	.	.	2	0.6	180	50.4
		20-24	759	9	1.2	1	0.1	359	47.6
		25-29	660	35	5.3	1	0.2	362	55.4
		30-34	313	10	3.3	2	0.7	174	57.2
		35+	158	4	2.5	104	66.2
	Years since diagnosis	5-9	440	15	3.4	1	0.2	.	.	1	0.2	.	.	1	0.2	247	56.9
		10-14	1099	25	2.3	1	0.1	.	.	5	0.5	679	62.2
		15-19	949	14	1.5	1	0.1	1	0.1	464	49.5
		20+	743	30	4.1	2	0.3	359	48.8
	Age at diagnosis	<1	63	1	1.6	1	1.6	38	61.3
		1-4	1591	31	2.0	1	0.1	.	.	3	0.2	788	49.9
		5-9	829	26	3.2	2	0.2	.	.	3	0.4	.	.	1	0.1	424	51.8
		10-14	476	16	3.4	1	0.2	324	68.2
		15-20	272	10	3.8	1	0.4	175	66.3
Females	All cases		2836	54	1.9	8	0.3	1	0.0	6	0.2	.	.	1	0.0	1427	50.8
	Age at baseline	<18	830	14	1.7	3	0.4	1	0.1	3	0.4	.	.	1	0.1	469	56.9
		18-19	307	2	0.7	1	0.3	150	49.3
		20-24	765	11	1.4	1	0.1	.	.	1	0.1	352	46.6
		25-29	547	15	2.8	2	0.4	250	46.0
		30-34	277	3	1.1	1	0.4	.	.	1	0.4	138	50.7
		35+	110	9	8.3	1	0.9	68	63.0
	Years since diagnosis	5-9	337	11	3.3	1	0.3	185	55.4
		10-14	950	11	1.2	3	0.3	.	.	5	0.5	.	.	1	0.1	578	61.6
		15-19	898	11	1.2	3	0.3	1	0.1	1	0.1	389	43.5
		20+	651	21	3.3	1	0.2	275	43.0
	Age at diagnosis	<1	64	1	1.6	2	3.1	1	1.6	1	1.6	43	68.3
		1-4	1439	26	1.8	2	0.1	.	.	2	0.1	.	.	1	0.1	665	46.6
		5-9	708	7	1.0	1	0.1	322	45.9
		10-14	464	10	2.2	3	0.6	.	.	2	0.4	288	62.6
		15-20	161	10	6.4	1	0.6	109	69.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	1	0.0	44	0.7	5	0.1	5	0.1	1	0.0	16	0.3	.	.
	Age at baseline	<18	1812	.	.	5	0.3	1	0.1	4	0.2	.	.
		18-19	666	.	.	8	1.2	.	.	1	0.2	.	.	1	0.2	.	.
		20-24	1524	1	0.1	13	0.9	2	0.1	4	0.3	.	.
		25-29	1207	.	.	10	0.8	1	0.1	3	0.2	.	.	5	0.4	.	.
		30-34	590	.	.	7	1.2	1	0.2	1	0.2	.	.	1	0.2	.	.
		35+	268	.	.	1	0.4	1	0.4	1	0.4	.	.
	Years since diagnosis	5-9	777	.	.	3	0.4	1	0.1	2	0.3	.	.
		10-14	2049	.	.	12	0.6	.	.	2	0.1	.	.	3	0.1	.	.
		15-19	1847	1	0.1	18	1.0	4	0.2	.	.	1	0.1	6	0.3	.	.
		20+	1394	.	.	11	0.8	.	.	3	0.2	.	.	5	0.4	.	.
	Age at diagnosis	<1	127	.	.	1	0.8	1	0.8	1	0.8	.	.
		1-4	3030	.	.	22	0.7	1	0.0	8	0.3	.	.
		5-9	1537	1	0.1	10	0.7	1	0.1	3	0.2	.	.	4	0.3	.	.
		10-14	940	.	.	9	1.0	.	.	2	0.2	.	.	1	0.1	.	.
		15-20	433	.	.	2	0.5	2	0.5	.	.	1	0.2	2	0.5	.	.
Males	All cases		3231	.	.	36	1.1	2	0.1	4	0.1	.	.	6	0.2	.	.
	Age at baseline	<18	982	.	.	3	0.3	1	0.1	.	.
		18-19	359	.	.	7	2.0	.	.	1	0.3	.	.	1	0.3	.	.
		20-24	759	.	.	12	1.6	1	0.1	1	0.1	.	.
		25-29	660	.	.	8	1.2	1	0.2	2	0.3	.	.	1	0.2	.	.
		30-34	313	.	.	5	1.6	.	.	1	0.3	.	.	1	0.3	.	.
		35+	158	.	.	1	0.6	1	0.6	.	.
	Years since diagnosis	5-9	440	.	.	3	0.7	1	0.2
		10-14	1099	.	.	9	0.8	.	.	2	0.2	.	.	1	0.1	.	.
		15-19	949	.	.	15	1.6	1	0.1	3	0.3	.	.
		20+	743	.	.	9	1.2	.	.	2	0.3	.	.	2	0.3	.	.
	Age at diagnosis	<1	63	.	.	1	1.6
		1-4	1591	.	.	17	1.1	4	0.3	.	.
		5-9	829	.	.	9	1.1	1	0.1	2	0.2
		10-14	476	.	.	7	1.5	.	.	2	0.4	.	.	1	0.2	.	.
		15-20	272	.	.	2	0.8	1	0.4	1	0.4	.	.
Females	All cases		2836	1	0.0	8	0.3	3	0.1	1	0.0	1	0.0	10	0.4	.	.
	Age at baseline	<18	830	.	.	2	0.2	1	0.1	3	0.4	.	.
		18-19	307	.	.	1	0.3
		20-24	765	1	0.1	1	0.1	1	0.1	3	0.4	.	.
		25-29	547	.	.	2	0.4	.	.	1	0.2	.	.	4	0.7	.	.
		30-34	277	.	.	2	0.7	1	0.4
		35+	110	1	0.9
	Years since diagnosis	5-9	337	2	0.6	.	.
		10-14	950	.	.	3	0.3	2	0.2	.	.
		15-19	898	1	0.1	3	0.3	3	0.3	.	.	1	0.1	3	0.3	.	.
		20+	651	.	.	2	0.3	.	.	1	0.2	.	.	3	0.5	.	.
	Age at diagnosis	<1	64	1	1.6	1	1.6	.	.
		1-4	1439	.	.	5	0.3	1	0.1	4	0.3	.	.
		5-9	708	1	0.1	1	0.1	.	.	1	0.1	.	.	4	0.6	.	.
		10-14	464	.	.	2	0.4
		15-20	161	1	0.6	.	.	1	0.6	1	0.6	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): AML

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		871	28	3.2	135	15.7	2	0.2	1	0.1	.	.	4	0.5	483	56.0
	Age at baseline	<18	225	11	4.9	28	12.6	1	0.4	1	0.4	.	.	4	1.8	135	60.3
		18-19	82	3	3.7	12	14.8	46	56.8
		20-24	191	3	1.6	24	12.6	1	0.5	97	51.3
		25-29	186	5	2.7	36	19.5	113	61.1
		30-34	118	4	3.4	22	19.0	67	57.8
		35+	69	2	2.9	13	19.4	25	36.8
	Years since diagnosis	5-9	81	.	.	6	7.6	2	2.5	51	63.8
		10-14	307	15	4.9	39	12.8	1	0.3	2	0.7	167	54.8
		15-19	301	6	2.0	56	18.7	1	0.3	1	0.3	168	56.2
		20+	182	7	3.9	34	19.1	97	54.2
	Age at diagnosis	<1	90	2	2.2	20	22.5	1	1.1	57	64.0
		1-4	299	16	5.4	40	13.4	1	0.3	1	0.3	.	.	4	1.3	168	56.4
		5-9	163	.	.	19	11.7	86	53.4
		10-14	182	5	2.8	34	19.2	110	61.8
		15-20	137	5	3.6	22	16.2	62	45.3
Males	All cases		427	10	2.4	67	15.9	3	0.7	229	54.3
	Age at baseline	<18	122	3	2.5	9	7.5	3	2.5	70	57.9
		18-19	42	1	2.4	7	16.7	24	57.1
		20-24	92	1	1.1	14	15.2	50	54.9
		25-29	82	2	2.5	17	21.0	42	51.9
		30-34	56	2	3.6	13	23.6	34	61.8
		35+	33	1	3.1	7	21.9	9	28.1
	Years since diagnosis	5-9	47	.	.	2	4.3	1	2.1	28	59.6
		10-14	152	4	2.7	18	12.0	2	1.3	79	52.7
		15-19	141	3	2.1	31	22.0	84	60.0
		20+	87	3	3.5	16	18.8	38	44.7
	Age at diagnosis	<1	39	1	2.6	8	21.1	28	73.7
		1-4	165	5	3.0	22	13.3	3	1.8	87	52.7
		5-9	75	.	.	8	10.8	37	50.7
		10-14	74	1	1.4	15	21.1	43	59.7
		15-20	74	3	4.1	14	18.9	34	45.9
Females	All cases		444	18	4.1	68	15.5	2	0.5	1	0.2	.	.	1	0.2	254	57.6
	Age at baseline	<18	103	8	7.8	19	18.4	1	1.0	1	1.0	.	.	1	1.0	65	63.1
		18-19	40	2	5.1	5	12.8	22	56.4
		20-24	99	2	2.0	10	10.2	1	1.0	47	48.0
		25-29	104	3	2.9	19	18.3	71	68.3
		30-34	62	2	3.3	9	14.8	33	54.1
		35+	36	1	2.8	6	17.1	16	44.4
	Years since diagnosis	5-9	34	.	.	4	12.1	1	3.0	23	69.7
		10-14	155	11	7.1	21	13.5	1	0.6	88	56.8
		15-19	160	3	1.9	25	15.7	1	0.6	1	0.6	84	52.8
		20+	95	4	4.3	18	19.4	59	62.8
	Age at diagnosis	<1	51	1	2.0	12	23.5	1	2.0	29	56.9
		1-4	134	11	8.3	18	13.5	1	0.8	1	0.8	.	.	1	0.8	81	60.9
		5-9	88	.	.	11	12.5	49	55.7
		10-14	108	4	3.8	19	17.9	67	63.2
		15-20	63	2	3.2	8	12.9	28	44.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		871	.	.	1	0.1	5	0.6	1	0.1	1	0.1	8	0.9	.	.
	Age at baseline	<18	225	.	.	1	0.4	1	0.4	1	0.4	.	.
		18-19	82	3	3.7	1	1.2	.	.
		20-24	191	1	0.5	.	.	1	0.5	1	0.5	.	.
		25-29	186	1	0.5	.	.	1	0.5	.	.
		30-34	118	1	0.9	.	.
		35+	69	3	4.4	.	.
	Years since diagnosis	5-9	81	.	.	1	1.3	1	1.3
		10-14	307	4	1.3	2	0.7	.	.
		15-19	301	1	0.3	.	.	5	1.7	.	.
		20+	182	1	0.6	1	0.6	.	.
	Age at diagnosis	<1	90	1	1.1	.	.	1	1.1	1	1.1	.	.
		1-4	299	1	0.3	2	0.7	.	.
		5-9	163	.	.	1	0.6	2	1.2	1	0.6	.	.	1	0.6	.	.
		10-14	182
		15-20	137	1	0.7	4	2.9	.	.
Males	All cases		427	.	.	1	0.2	1	0.2	4	0.9	.	.
	Age at baseline	<18	122	.	.	1	0.8	1	0.8	.	.
		18-19	42
		20-24	92	1	1.1	1	1.1	.	.
		25-29	82
		30-34	56	1	1.8	.	.
		35+	33	1	3.1	.	.
	Years since diagnosis	5-9	47	.	.	1	2.1	1	2.1
		10-14	152	2	1.3	.	.
		15-19	141	2	1.4	.	.
		20+	87
	Age at diagnosis	<1	39	1	2.6	.	.
		1-4	165
		5-9	75	.	.	1	1.4	1	1.4	.	.
		10-14	74
		15-20	74	1	1.4	2	2.7	.	.
Females	All cases		444	4	0.9	1	0.2	1	0.2	4	0.9	.	.
	Age at baseline	<18	103	1	1.0
		18-19	40	3	7.7	1	2.6	.	.
		20-24	99	1	1.0
		25-29	104	1	1.0	.	.	1	1.0	.	.
		30-34	62
		35+	36	2	5.6	.	.
	Years since diagnosis	5-9	34
		10-14	155	4	2.6
		15-19	160	1	0.6	.	.	3	1.9	.	.
		20+	95	1	1.1	1	1.1	.	.
	Age at diagnosis	<1	51	1	2.0	.	.	1	2.0
		1-4	134	1	0.8	2	1.5	.	.
		5-9	88	2	2.3	1	1.1
		10-14	108
		15-20	63	2	3.2	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4184	59	1.4	4	0.1	387	9.4	607	14.7	.	.	716	17.3	564	13.7
	Age at baseline	<18	891	17	1.9	1	0.1	114	12.9	152	17.3	.	.	202	22.9	175	19.8
		18-19	349	3	0.9	2	0.6	68	19.9	48	14.2	.	.	70	20.6	61	17.9
		20-24	1093	20	1.9	1	0.1	112	10.4	144	13.4	.	.	213	19.7	174	16.1
		25-29	1021	13	1.3	.	.	71	7.0	172	17.1	.	.	152	15.1	95	9.4
		30-34	581	3	0.5	.	.	15	2.6	71	12.4	.	.	60	10.4	46	8.0
		35+	249	3	1.2	.	.	7	2.9	20	8.2	.	.	19	7.8	13	5.3
	Years since diagnosis	5-9	428	16	3.8	2	0.5	34	8.1	101	24.2	.	.	109	26.0	87	20.7
		10-14	1424	15	1.1	1	0.1	133	9.4	202	14.4	.	.	255	18.1	189	13.4
		15-19	1325	14	1.1	1	0.1	172	13.2	164	12.6	.	.	193	14.8	171	13.1
		20+	1007	14	1.4	.	.	48	4.8	140	14.1	.	.	159	15.9	117	11.7
	Age at diagnosis	<1	205	8	3.9	.	.	50	24.5	27	13.3	.	.	48	23.5	54	26.5
		1-4	1223	18	1.5	3	0.2	173	14.3	157	13.1	.	.	244	20.2	225	18.6
		5-9	1326	14	1.1	.	.	102	7.8	226	17.3	.	.	247	18.9	173	13.2
		10-14	996	10	1.0	1	0.1	48	4.9	148	15.1	.	.	143	14.5	87	8.8
		15-20	434	9	2.1	.	.	14	3.3	49	11.6	.	.	34	8.0	25	5.9
Males	All cases		2276	34	1.5	3	0.1	226	10.1	375	16.8	.	.	428	19.1	326	14.6
	Age at baseline	<18	494	10	2.1	.	.	65	13.3	97	19.9	.	.	127	26.1	110	22.6
		18-19	176	1	0.6	2	1.2	36	20.9	26	15.2	.	.	38	22.2	30	17.5
		20-24	584	11	1.9	1	0.2	70	12.1	90	15.7	.	.	129	22.4	107	18.5
		25-29	579	9	1.6	.	.	42	7.3	113	19.8	.	.	94	16.4	54	9.4
		30-34	309	1	0.3	.	.	8	2.6	36	11.9	.	.	29	9.5	18	5.9
		35+	134	2	1.6	.	.	5	3.9	13	10.2	.	.	11	8.6	7	5.5
	Years since diagnosis	5-9	242	9	3.8	1	0.4	19	8.0	57	24.3	.	.	62	26.3	52	22.0
		10-14	766	7	0.9	1	0.1	75	9.9	135	17.9	.	.	159	21.0	113	14.9
		15-19	720	9	1.3	1	0.1	102	14.4	102	14.5	.	.	120	17.0	104	14.7
		20+	548	9	1.7	.	.	30	5.6	81	15.1	.	.	87	16.1	57	10.5
	Age at diagnosis	<1	121	5	4.2	.	.	30	25.0	19	15.8	.	.	29	24.2	35	29.2
		1-4	647	9	1.4	2	0.3	97	15.2	98	15.4	.	.	146	22.8	129	20.2
		5-9	738	10	1.4	.	.	64	8.8	141	19.4	.	.	154	21.2	101	13.9
		10-14	526	6	1.2	1	0.2	26	5.0	85	16.4	.	.	78	15.0	45	8.7
		15-20	244	4	1.7	.	.	9	3.8	32	13.7	.	.	21	8.9	16	6.8
Females	All cases		1908	25	1.3	1	0.1	161	8.5	232	12.3	.	.	288	15.3	238	12.6
	Age at baseline	<18	397	7	1.8	1	0.3	49	12.4	55	14.0	.	.	75	19.0	65	16.4
		18-19	173	2	1.2	.	.	32	18.9	22	13.1	.	.	32	19.0	31	18.3
		20-24	509	9	1.8	.	.	42	8.4	54	10.8	.	.	84	16.7	67	13.3
		25-29	442	4	0.9	.	.	29	6.7	59	13.5	.	.	58	13.3	41	9.4
		30-34	272	2	0.7	.	.	7	2.6	35	12.9	.	.	31	11.4	28	10.3
		35+	115	1	0.9	.	.	2	1.7	7	6.1	.	.	8	7.0	6	5.2
	Years since diagnosis	5-9	186	7	3.8	1	0.5	15	8.2	44	24.0	.	.	47	25.5	35	19.0
		10-14	658	8	1.2	.	.	58	8.9	67	10.3	.	.	96	14.8	76	11.7
		15-19	605	5	0.8	.	.	70	11.7	62	10.4	.	.	73	12.2	67	11.2
		20+	459	5	1.1	.	.	18	3.9	59	12.9	.	.	72	15.8	60	13.1
	Age at diagnosis	<1	84	3	3.6	.	.	20	23.8	8	9.6	.	.	19	22.6	19	22.6
		1-4	576	9	1.6	1	0.2	76	13.4	59	10.4	.	.	98	17.3	96	16.9
		5-9	588	4	0.7	.	.	38	6.5	85	14.6	.	.	93	16.0	72	12.3
		10-14	470	4	0.9	.	.	22	4.7	63	13.5	.	.	65	13.9	42	9.0
		15-20	190	5	2.7	.	.	5	2.7	17	9.1	.	.	13	6.9	9	4.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4184	50	1.2	73	1.8	8	0.2	56	1.4	353	8.6	45	1.1	28	0.7
	Age at baseline	<18	891	17	1.9	22	2.5	4	0.5	28	3.2	122	13.8	15	1.7	19	2.2
		18-19	349	1	0.3	8	2.3	1	0.3	5	1.5	27	7.9	10	2.9	3	0.9
		20-24	1093	12	1.1	21	1.9	.	.	14	1.3	79	7.3	12	1.1	1	0.1
		25-29	1021	11	1.1	12	1.2	3	0.3	6	0.6	78	7.7	7	0.7	5	0.5
		30-34	581	8	1.4	7	1.2	.	.	2	0.3	33	5.7	1	0.2	.	.
		35+	249	1	0.4	3	1.2	.	.	1	0.4	14	5.8
	Years since diagnosis	5-9	428	11	2.6	12	2.9	2	0.5	11	2.6	75	17.9	11	2.6	6	1.4
		10-14	1424	16	1.1	14	1.0	5	0.4	22	1.6	123	8.7	14	1.0	19	1.3
		15-19	1325	4	0.3	34	2.6	1	0.1	14	1.1	67	5.1	17	1.3	3	0.2
		20+	1007	19	1.9	13	1.3	.	.	9	0.9	88	8.8	3	0.3	.	.
	Age at diagnosis	<1	205	7	3.4	7	3.4	.	.	9	4.4	38	18.6	4	2.0	7	3.4
		1-4	1223	9	0.7	32	2.6	3	0.2	29	2.4	111	9.2	23	1.9	11	0.9
		5-9	1326	20	1.5	15	1.1	2	0.2	10	0.8	105	8.0	8	0.6	5	0.4
		10-14	996	10	1.0	14	1.4	2	0.2	7	0.7	69	7.0	6	0.6	2	0.2
		15-20	434	4	0.9	5	1.2	1	0.2	1	0.2	30	7.1	4	0.9	3	0.7
Males	All cases		2276	31	1.4	40	1.8	3	0.1	29	1.3	208	9.3	28	1.2	15	0.7
	Age at baseline	<18	494	15	3.1	16	3.3	2	0.4	15	3.1	80	16.4	9	1.8	10	2.1
		18-19	176	1	0.6	1	0.6	.	.	1	0.6	9	5.3	5	2.9	1	0.6
		20-24	584	6	1.0	12	2.1	.	.	7	1.2	43	7.5	9	1.6	1	0.2
		25-29	579	6	1.0	6	1.0	1	0.2	5	0.9	53	9.3	4	0.7	3	0.5
		30-34	309	3	1.0	4	1.3	.	.	1	0.3	15	4.9	1	0.3	.	.
		35+	134	.	.	1	0.8	8	6.3
	Years since diagnosis	5-9	242	7	3.0	5	2.1	2	0.8	7	3.0	45	19.1	7	3.0	3	1.3
		10-14	766	14	1.8	10	1.3	1	0.1	13	1.7	79	10.4	7	0.9	9	1.2
		15-19	720	3	0.4	18	2.5	.	.	6	0.8	39	5.5	11	1.6	3	0.4
		20+	548	7	1.3	7	1.3	.	.	3	0.6	45	8.3	3	0.6	.	.
	Age at diagnosis	<1	121	5	4.2	6	5.0	.	.	3	2.5	22	18.3	3	2.5	5	4.2
		1-4	647	6	0.9	17	2.7	.	.	14	2.2	62	9.7	15	2.3	5	0.8
		5-9	738	14	1.9	9	1.2	2	0.3	7	1.0	65	8.9	5	0.7	2	0.3
		10-14	526	4	0.8	6	1.2	.	.	4	0.8	38	7.3	2	0.4	1	0.2
		15-20	244	2	0.9	2	0.9	1	0.4	1	0.4	21	8.9	3	1.3	2	0.9
Females	All cases		1908	19	1.0	33	1.7	5	0.3	27	1.4	145	7.7	17	0.9	13	0.7
	Age at baseline	<18	397	2	0.5	6	1.5	2	0.5	13	3.3	42	10.6	6	1.5	9	2.3
		18-19	173	.	.	7	4.1	1	0.6	4	2.4	18	10.7	5	3.0	2	1.2
		20-24	509	6	1.2	9	1.8	.	.	7	1.4	36	7.2	3	0.6	.	.
		25-29	442	5	1.1	6	1.4	2	0.5	1	0.2	25	5.7	3	0.7	2	0.5
		30-34	272	5	1.8	3	1.1	.	.	1	0.4	18	6.6
		35+	115	1	0.9	2	1.7	.	.	1	0.9	6	5.2
	Years since diagnosis	5-9	186	4	2.2	7	3.8	.	.	4	2.2	30	16.3	4	2.2	3	1.6
		10-14	658	2	0.3	4	0.6	4	0.6	9	1.4	44	6.8	7	1.1	10	1.5
		15-19	605	1	0.2	16	2.7	1	0.2	8	1.3	28	4.7	6	1.0	.	.
		20+	459	12	2.6	6	1.3	.	.	6	1.3	43	9.4
	Age at diagnosis	<1	84	2	2.4	1	1.2	.	.	6	7.1	16	19.0	1	1.2	2	2.4
		1-4	576	3	0.5	15	2.6	3	0.5	15	2.6	49	8.6	8	1.4	6	1.1
		5-9	588	6	1.0	6	1.0	.	.	3	0.5	40	6.9	3	0.5	3	0.5
		10-14	470	6	1.3	8	1.7	2	0.4	3	0.6	31	6.7	4	0.9	1	0.2
		15-20	190	2	1.1	3	1.6	9	4.8	1	0.5	1	0.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Astrocytomas

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2509	32	1.3	.	.	205	8.3	217	8.8	.	.	108	4.3	68	2.7
	Age at baseline	<18	493	7	1.4	.	.	73	14.9	59	12.1	.	.	33	6.7	29	5.9
		18-19	202	1	0.5	.	.	39	19.8	13	6.6	.	.	7	3.6	7	3.6
		20-24	662	10	1.5	.	.	56	8.6	49	7.5	.	.	30	4.6	23	3.5
		25-29	629	10	1.6	.	.	32	5.2	57	9.2	.	.	27	4.3	8	1.3
		30-34	357	2	0.6	.	.	3	0.8	30	8.5	.	.	10	2.8	1	0.3
		35+	166	2	1.2	.	.	2	1.2	9	5.5	.	.	1	0.6	.	.
	Years since diagnosis	5-9	219	7	3.2	.	.	12	5.5	39	18.1	.	.	21	9.7	10	4.6
		10-14	838	8	1.0	.	.	84	10.1	82	9.9	.	.	27	3.3	18	2.2
		15-19	778	9	1.2	.	.	86	11.2	46	6.0	.	.	19	2.5	23	3.0
		20+	674	8	1.2	.	.	23	3.4	50	7.5	.	.	41	6.1	17	2.5
	Age at diagnosis	<1	144	5	3.5	.	.	40	27.8	21	14.7	.	.	22	15.3	22	15.3
		1-4	741	8	1.1	.	.	97	13.3	47	6.4	.	.	36	4.9	34	4.6
		5-9	750	6	0.8	.	.	44	5.9	69	9.3	.	.	29	3.9	9	1.2
		10-14	599	5	0.8	.	.	17	2.9	52	8.8	.	.	15	2.5	1	0.2
		15-20	275	8	3.0	.	.	7	2.6	28	10.4	.	.	6	2.2	2	0.7
Males	All cases		1302	18	1.4	.	.	112	8.7	132	10.3	.	.	68	5.3	49	3.8
	Age at baseline	<18	258	4	1.6	.	.	38	14.9	41	16.1	.	.	27	10.6	23	9.0
		18-19	102	21	21.0	9	9.0	.	.	5	5.0	5	5.0
		20-24	325	5	1.5	.	.	36	11.1	28	8.7	.	.	18	5.6	16	5.0
		25-29	351	6	1.7	.	.	15	4.3	36	10.4	.	.	14	4.0	5	1.4
		30-34	178	1	0.6	.	.	1	0.6	11	6.3	.	.	4	2.3	.	.
		35+	88	2	2.3	.	.	1	1.2	7	8.1
	Years since diagnosis	5-9	117	4	3.4	.	.	6	5.1	22	18.8	.	.	15	12.8	7	6.0
		10-14	437	2	0.5	.	.	45	10.4	57	13.2	.	.	22	5.1	17	3.9
		15-19	391	5	1.3	.	.	47	12.2	28	7.3	.	.	11	2.9	16	4.2
		20+	357	7	2.0	.	.	14	4.0	25	7.1	.	.	20	5.6	9	2.5
	Age at diagnosis	<1	81	4	4.9	.	.	22	27.2	15	18.5	.	.	16	19.8	18	22.2
		1-4	373	4	1.1	.	.	51	13.9	32	8.7	.	.	25	6.8	24	6.5
		5-9	394	4	1.0	.	.	27	6.9	41	10.5	.	.	17	4.4	4	1.0
		10-14	302	2	0.7	.	.	7	2.3	27	9.1	.	.	7	2.3	1	0.3
		15-20	152	4	2.7	.	.	5	3.4	17	11.4	.	.	3	2.0	2	1.3
Females	All cases		1207	14	1.2	.	.	93	7.8	85	7.1	.	.	40	3.3	19	1.6
	Age at baseline	<18	235	3	1.3	.	.	35	14.9	18	7.7	.	.	6	2.6	6	2.6
		18-19	100	1	1.0	.	.	18	18.6	4	4.1	.	.	2	2.1	2	2.1
		20-24	337	5	1.5	.	.	20	6.0	21	6.3	.	.	12	3.6	7	2.1
		25-29	278	4	1.5	.	.	17	6.2	21	7.7	.	.	13	4.7	3	1.1
		30-34	179	1	0.6	.	.	2	1.1	19	10.7	.	.	6	3.4	1	0.6
		35+	78	1	1.3	2	2.6	.	.	1	1.3	.	.
	Years since diagnosis	5-9	102	3	3.0	.	.	6	6.0	17	17.2	.	.	6	6.0	3	3.0
		10-14	401	6	1.5	.	.	39	9.8	25	6.3	.	.	5	1.3	1	0.3
		15-19	387	4	1.0	.	.	39	10.2	18	4.7	.	.	8	2.1	7	1.8
		20+	317	1	0.3	.	.	9	2.9	25	7.9	.	.	21	6.7	8	2.5
	Age at diagnosis	<1	63	1	1.6	.	.	18	28.6	6	9.7	.	.	6	9.5	4	6.3
		1-4	368	4	1.1	.	.	46	12.7	15	4.1	.	.	11	3.0	10	2.8
		5-9	356	2	0.6	.	.	17	4.8	28	7.9	.	.	12	3.4	5	1.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Astrocytomas

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2509	45	1.8	17	0.7	.	.	19	0.8	170	6.9	8	0.3	22	0.9
	Age at baseline	<18	493	14	2.9	8	1.6	.	.	9	1.8	54	11.0	.	.	15	3.1
		18-19	202	1	0.5	3	1.5	.	.	3	1.5	13	6.6	1	0.5	2	1.0
		20-24	662	11	1.7	4	0.6	.	.	4	0.6	38	5.8	4	0.6	1	0.2
		25-29	629	10	1.6	1	0.2	.	.	1	0.2	40	6.4	3	0.5	4	0.6
		30-34	357	8	2.2	1	0.3	18	5.1
		35+	166	1	0.6	1	0.6	.	.	1	0.6	7	4.3
	Years since diagnosis	5-9	219	10	4.6	3	1.4	.	.	3	1.4	27	12.4	1	0.5	4	1.9
		10-14	838	13	1.6	5	0.6	.	.	6	0.7	67	8.1	1	0.1	15	1.8
		15-19	778	3	0.4	5	0.7	.	.	5	0.7	35	4.6	5	0.7	3	0.4
		20+	674	19	2.8	4	0.6	.	.	5	0.7	41	6.1	1	0.1	.	.
	Age at diagnosis	<1	144	7	4.9	4	2.8	.	.	7	4.9	28	19.4	1	0.7	7	4.9
		1-4	741	7	1.0	10	1.4	.	.	9	1.2	42	5.7	3	0.4	7	1.0
		5-9	750	18	2.4	46	6.2	1	0.1	4	0.5
		10-14	599	9	1.5	2	0.3	.	.	3	0.5	35	5.9	2	0.3	2	0.3
		15-20	275	4	1.5	1	0.4	19	7.1	1	0.4	2	0.7
Males	All cases		1302	27	2.1	11	0.9	.	.	8	0.6	103	8.0	4	0.3	12	0.9
	Age at baseline	<18	258	13	5.1	7	2.7	.	.	5	2.0	40	15.7	.	.	8	3.1
		18-19	102	1	1.0	5	5.0	.	.	1	1.0
		20-24	325	5	1.5	3	0.9	.	.	2	0.6	19	5.9	3	0.9	1	0.3
		25-29	351	5	1.4	1	0.3	26	7.5	1	0.3	2	0.6
		30-34	178	3	1.7	8	4.5
		35+	88	.	.	1	1.2	5	5.8
	Years since diagnosis	5-9	117	7	6.0	1	0.9	.	.	2	1.7	16	13.7	1	0.9	2	1.7
		10-14	437	11	2.5	4	0.9	.	.	4	0.9	47	10.9	.	.	7	1.6
		15-19	391	2	0.5	3	0.8	21	5.5	2	0.5	3	0.8
		20+	357	7	2.0	3	0.8	.	.	2	0.6	19	5.4	1	0.3	.	.
	Age at diagnosis	<1	81	5	6.2	4	4.9	.	.	2	2.5	17	21.0	1	1.2	5	6.2
		1-4	373	5	1.4	6	1.6	.	.	5	1.4	25	6.8	2	0.5	3	0.8
		5-9	394	12	3.1	31	8.0	.	.	2	0.5
		10-14	302	3	1.0	1	0.3	.	.	1	0.3	17	5.7	.	.	1	0.3
		15-20	152	2	1.3	13	8.7	1	0.7	1	0.7
Females	All cases		1207	18	1.5	6	0.5	.	.	11	0.9	67	5.6	4	0.3	10	0.8
	Age at baseline	<18	235	1	0.4	1	0.4	.	.	4	1.7	14	6.0	.	.	7	3.0
		18-19	100	.	.	3	3.1	.	.	3	3.1	8	8.2	1	1.0	1	1.0
		20-24	337	6	1.8	1	0.3	.	.	2	0.6	19	5.7	1	0.3	.	.
		25-29	278	5	1.8	1	0.4	14	5.1	2	0.7	2	0.7
		30-34	179	5	2.8	1	0.6	10	5.6
		35+	78	1	1.3	1	1.3	2	2.6
	Years since diagnosis	5-9	102	3	3.0	2	2.0	.	.	1	1.0	11	11.0	.	.	2	2.0
		10-14	401	2	0.5	1	0.3	.	.	2	0.5	20	5.1	1	0.3	8	2.0
		15-19	387	1	0.3	2	0.5	.	.	5	1.3	14	3.7	3	0.8	.	.
		20+	317	12	3.8	1	0.3	.	.	3	1.0	22	7.0
	Age at diagnosis	<1	63	2	3.2	5	7.9	11	17.5	.	.	2	3.2
		1-4	368	2	0.6	4	1.1	.	.	4	1.1	17	4.7	1	0.3	4	1.1
		5-9	356	6	1.7	15	4.2	1	0.3	2	0.6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Astrocytomas

				BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	297	3	1.0	.	.	10	3.4	25	8.5	.	.	8	2.7	.	.
		15-20	123	4	3.3	.	.	2	1.7	11	9.2	.	.	3	2.5	.	.

Chemotherapy agents - Alkylating agents (including Platinum drugs): Astrocytomas

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	297	6	2.0	1	0.3	.	.	2	0.7	18	6.1	2	0.7	1	0.3
		15-20	123	2	1.7	1	0.8	6	5.0	.	.	1	0.8

Chemotherapy agents - Alkylating agents (including Platinum drugs): Medulloblastoma/PNET

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		979	19	2.0	4	0.4	121	12.6	334	34.8	.	.	506	52.5	391	40.6
	Age at baseline	<18	233	8	3.5	1	0.4	21	9.1	75	32.8	.	.	130	56.8	105	45.7
		18-19	77	1	1.4	2	2.7	16	21.6	28	37.8	.	.	46	62.2	34	45.9
		20-24	273	6	2.2	1	0.4	39	14.5	87	32.3	.	.	157	58.1	126	46.7
		25-29	236	3	1.3	.	.	31	13.2	95	40.8	.	.	112	48.1	75	32.2
		30-34	126	1	0.8	.	.	9	7.2	39	31.5	.	.	47	37.6	41	32.8
		35+	34	5	15.6	10	31.3	.	.	14	43.8	10	31.3
	Years since diagnosis	5-9	119	6	5.2	2	1.7	13	11.3	49	42.6	.	.	62	53.9	54	47.0
		10-14	333	6	1.8	1	0.3	35	10.6	104	31.6	.	.	199	60.5	144	43.6
		15-19	323	4	1.3	1	0.3	51	16.0	107	33.6	.	.	145	45.6	112	35.2
		20+	204	3	1.5	.	.	22	11.0	74	37.2	.	.	100	49.8	81	40.3
	Age at diagnosis	<1	23	1	4.5	.	.	5	22.7	3	13.6	.	.	15	68.2	17	77.3
		1-4	279	8	2.9	3	1.1	43	15.7	87	32.0	.	.	153	55.8	130	47.3
		5-9	402	7	1.8	.	.	44	11.0	139	34.9	.	.	205	51.5	153	38.4
		10-14	217	3	1.4	1	0.5	23	10.7	88	41.1	.	.	113	52.8	74	34.6
		15-20	58	6	10.9	17	30.9	.	.	20	36.4	17	30.9
Males	All cases		599	12	2.0	3	0.5	82	13.9	216	36.9	.	.	316	53.8	229	39.0
	Age at baseline	<18	141	5	3.6	.	.	15	10.9	50	36.2	.	.	82	59.4	64	46.4
		18-19	43	.	.	2	4.9	9	22.0	14	34.1	.	.	25	61.0	17	41.5
		20-24	177	4	2.3	1	0.6	27	15.4	57	32.8	.	.	101	57.7	83	47.4
		25-29	145	3	2.1	.	.	22	15.3	67	46.9	.	.	76	53.1	44	30.8
		30-34	71	5	7.1	23	33.3	.	.	24	34.3	16	22.9
		35+	22	4	20.0	5	25.0	.	.	8	40.0	5	25.0
	Years since diagnosis	5-9	72	3	4.4	1	1.5	9	13.2	29	42.6	.	.	35	51.5	33	48.5
		10-14	196	4	2.1	1	0.5	22	11.3	71	36.6	.	.	126	64.9	84	43.3
		15-19	207	3	1.5	1	0.5	36	17.6	68	33.3	.	.	93	45.6	70	34.3
		20+	124	2	1.7	.	.	15	12.4	48	40.3	.	.	62	51.2	42	34.7
	Age at diagnosis	<1	16	1	6.7	.	.	4	26.7	3	20.0	.	.	9	60.0	10	66.7
		1-4	168	4	2.4	2	1.2	29	17.6	58	35.6	.	.	96	58.2	76	46.1
		5-9	257	5	2.0	.	.	31	12.2	93	36.6	.	.	134	52.8	94	37.0
		10-14	123	2	1.7	1	0.8	15	12.4	50	41.3	.	.	65	53.7	40	33.1
		15-20	35	3	9.4	12	37.5	.	.	12	37.5	9	28.1
Females	All cases		380	7	1.9	1	0.3	39	10.4	118	31.4	.	.	190	50.5	162	43.0
	Age at baseline	<18	92	3	3.3	1	1.1	6	6.5	25	27.5	.	.	48	52.7	41	44.6
		18-19	34	1	3.0	.	.	7	21.2	14	42.4	.	.	21	63.6	17	51.5
		20-24	96	2	2.1	.	.	12	12.8	30	31.6	.	.	56	58.9	43	45.3
		25-29	91	9	10.0	28	31.1	.	.	36	40.0	31	34.4
		30-34	55	1	1.8	.	.	4	7.3	16	29.1	.	.	23	41.8	25	45.5
		35+	12	1	8.3	5	41.7	.	.	6	50.0	5	41.7
	Years since diagnosis	5-9	47	3	6.4	1	2.1	4	8.5	20	42.6	.	.	27	57.4	21	44.7
		10-14	137	2	1.5	.	.	13	9.6	33	24.4	.	.	73	54.1	60	44.1
		15-19	116	1	0.9	.	.	15	13.2	39	34.2	.	.	52	45.6	42	36.8
		20+	80	1	1.3	.	.	7	8.9	26	32.5	.	.	38	47.5	39	48.8
	Age at diagnosis	<1	7	1	14.3	6	85.7	7	.
		1-4	111	4	3.6	1	0.9	14	12.8	29	26.6	.	.	57	52.3	54	49.1
		5-9	145	2	1.4	.	.	13	9.0	46	31.9	.	.	71	49.3	59	41.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Medulloblastoma/PNET

			DTIC		Ifosfamide		Melfhalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		979	4	0.4	32	3.3	7	0.7	30	3.1	140	14.5	30	3.1	4	0.4
	Age at baseline	<18	233	2	0.9	6	2.6	4	1.7	13	5.7	50	21.7	13	5.7	3	1.3
		18-19	77	.	.	1	1.4	.	.	2	2.7	8	10.8	6	8.1	1	1.4
		20-24	273	1	0.4	11	4.1	.	.	9	3.3	31	11.5	7	2.6	.	.
		25-29	236	1	0.4	6	2.6	3	1.3	5	2.1	30	12.8	3	1.3	.	.
		30-34	126	.	.	6	4.8	.	.	1	0.8	14	11.2	1	0.8	.	.
		35+	34	.	.	2	6.3	7	21.9
	Years since diagnosis	5-9	119	.	.	5	4.3	2	1.7	6	5.2	33	28.7	9	7.8	2	1.7
		10-14	333	3	0.9	5	1.5	5	1.5	12	3.6	42	12.7	11	3.3	2	0.6
		15-19	323	1	0.3	13	4.1	.	.	9	2.8	27	8.5	8	2.5	.	.
		20+	204	.	.	9	4.5	.	.	3	1.5	38	18.9	2	1.0	.	.
	Age at diagnosis	<1	23	.	.	2	9.1	.	.	2	9.1	5	22.7	1	4.5	.	.
		1-4	279	1	0.4	9	3.3	2	0.7	14	5.1	50	18.2	18	6.6	3	1.1
		5-9	402	2	0.5	8	2.0	2	0.5	9	2.3	50	12.5	4	1.0	1	0.3
		10-14	217	1	0.5	9	4.2	2	0.9	4	1.9	28	13.1	4	1.9	.	.
		15-20	58	.	.	4	7.3	1	1.8	1	1.8	7	12.7	3	5.5	.	.
Males	All cases		599	4	0.7	16	2.7	3	0.5	17	2.9	86	14.7	20	3.4	1	0.2
	Age at baseline	<18	141	2	1.4	3	2.2	2	1.4	6	4.3	32	23.2	8	5.8	1	0.7
		18-19	43	1	2.4	2	4.9	3	7.3	.	.
		20-24	177	1	0.6	7	4.0	.	.	5	2.9	20	11.5	6	3.4	.	.
		25-29	145	1	0.7	3	2.1	1	0.7	4	2.8	23	16.0	2	1.4	.	.
		30-34	71	.	.	3	4.3	.	.	1	1.4	6	8.6	1	1.4	.	.
		35+	22	3	15.0
	Years since diagnosis	5-9	72	.	.	2	2.9	2	2.9	3	4.4	21	30.9	6	8.8	1	1.5
		10-14	196	3	1.5	3	1.5	1	0.5	7	3.6	26	13.4	6	3.1	.	.
		15-19	207	1	0.5	7	3.4	.	.	6	2.9	16	7.8	6	2.9	.	.
		20+	124	.	.	4	3.3	.	.	1	0.8	23	19.0	2	1.7	.	.
	Age at diagnosis	<1	16	.	.	1	6.7	.	.	1	6.7	4	26.7	1	6.7	.	.
		1-4	168	1	0.6	4	2.4	.	.	6	3.6	29	17.7	11	6.7	1	0.6
		5-9	257	2	0.8	6	2.4	2	0.8	6	2.4	32	12.5	4	1.6	.	.
		10-14	123	1	0.8	3	2.5	.	.	3	2.5	16	13.2	2	1.7	.	.
		15-20	35	.	.	2	6.3	1	3.1	1	3.1	5	15.6	2	6.3	.	.
Females	All cases		380	.	.	16	4.2	4	1.1	13	3.4	54	14.3	10	2.7	3	0.8
	Age at baseline	<18	92	.	.	3	3.3	2	2.2	7	7.6	18	19.6	5	5.4	2	2.2
		18-19	34	.	.	1	3.0	.	.	1	3.0	6	18.2	3	9.1	1	3.0
		20-24	96	.	.	4	4.2	.	.	4	4.2	11	11.6	1	1.1	.	.
		25-29	91	.	.	3	3.3	2	2.2	1	1.1	7	7.8	1	1.1	.	.
		30-34	55	.	.	3	5.5	8	14.5
		35+	12	.	.	2	16.7	4	33.3
	Years since diagnosis	5-9	47	.	.	3	6.4	.	.	3	6.4	12	25.5	3	6.4	1	2.1
		10-14	137	.	.	2	1.5	4	2.9	5	3.7	16	11.8	5	3.7	2	1.5
		15-19	116	.	.	6	5.3	.	.	3	2.6	11	9.6	2	1.8	.	.
		20+	80	.	.	5	6.3	.	.	2	2.5	15	18.8
	Age at diagnosis	<1	7	.	.	1	14.3	.	.	1	14.3	1	14.3
		1-4	111	.	.	5	4.5	2	1.8	8	7.3	21	19.1	7	6.4	2	1.8
		5-9	145	.	.	2	1.4	.	.	3	2.1	18	12.5	.	.	1	0.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

**Chemotherapy agents - Alkylating agents (including Platinum drugs):
Medulloblastoma/PNET**

				BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	94	1	1.1	.	.	8	8.6	38	40.9	.	.	48	51.6	34	36.6
		15-20	23	3	13.0	5	21.7	.	.	8	34.8	8	34.8

*CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included*

**Chemotherapy agents - Alkylating agents (including Platinum drugs):
Medulloblastoma/PNET**

			DTIC		Ifosfamide		Melfhalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	94	.	.	6	6.5	2	2.2	1	1.1	12	12.9	2	2.2	.	.
		15-20	23	.	.	2	8.7	2	8.7	1	4.3	.	.

*CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included*

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	69	2.5	8	0.3	18	0.6	146	5.2	39	1.4	46	1.6	839	30.1
	Age at baseline	<18	55	3	5.5	1	1.8	1	1.8	4	7.3	1	1.8	.	.	14	25.5
		18-19	55	2	3.6	.	.	1	1.8	18	32.7
		20-24	328	14	4.3	3	0.9	2	0.6	23	7.1	8	2.5	7	2.2	105	32.6
		25-29	733	20	2.8	2	0.3	6	0.8	43	5.9	5	0.7	9	1.2	273	37.8
		30-34	862	15	1.8	1	0.1	8	0.9	49	5.8	10	1.2	17	2.0	278	32.8
		35+	794	17	2.2	1	0.1	1	0.1	25	3.2	15	1.9	12	1.5	151	19.3
	Years since diagnosis	5-9	221	21	9.7	3	1.4	2	0.9	26	12.0	8	3.7	11	5.1	58	26.7
		10-14	867	20	2.3	3	0.4	8	0.9	49	5.7	7	0.8	8	0.9	333	38.9
		15-19	930	15	1.6	1	0.1	8	0.9	42	4.6	8	0.9	13	1.4	269	29.4
		20+	809	13	1.6	1	0.1	.	.	29	3.6	16	2.0	14	1.8	179	22.5
	Age at diagnosis	1-4	71	1	1.4	.	.	18	25.7
		5-9	353	3	0.9	1	0.3	1	0.3	22	6.3	4	1.1	1	0.3	108	30.9
		10-14	1026	19	1.9	5	0.5	6	0.6	48	4.7	10	1.0	24	2.4	341	33.7
		15-20	1377	47	3.5	2	0.1	11	0.8	76	5.6	24	1.8	21	1.5	372	27.5
Males	All cases		1458	37	2.6	4	0.3	10	0.7	85	5.9	15	1.0	20	1.4	416	29.0
	Age at baseline	<18	42	2	4.8	1	2.4	1	2.4	4	9.5	1	2.4	.	.	12	28.6
		18-19	44	2	4.5	.	.	1	2.3	13	29.5
		20-24	207	8	4.0	2	1.0	.	.	17	8.4	6	3.0	3	1.5	64	31.7
		25-29	401	13	3.3	1	0.3	5	1.3	25	6.3	1	0.3	4	1.0	132	33.5
		30-34	429	11	2.6	.	.	4	0.9	26	6.1	3	0.7	7	1.6	135	31.9
		35+	335	3	0.9	11	3.3	4	1.2	5	1.5	60	18.1
	Years since diagnosis	5-9	126	13	10.6	2	1.6	1	0.8	19	15.4	6	4.9	5	4.1	35	28.5
		10-14	441	13	3.0	1	0.2	5	1.1	28	6.4	2	0.5	4	0.9	158	36.3
		15-19	492	8	1.7	1	0.2	4	0.8	25	5.2	3	0.6	6	1.2	143	29.6
		20+	399	3	0.8	13	3.3	4	1.0	5	1.3	80	20.3
	Age at diagnosis	1-4	52	1	2.0	.	.	13	25.5
		5-9	259	2	0.8	1	0.4	1	0.4	19	7.4	1	0.4	.	.	74	28.9
		10-14	522	10	1.9	2	0.4	4	0.8	21	4.1	5	1.0	8	1.6	155	30.1
		15-20	625	25	4.1	1	0.2	5	0.8	45	7.3	8	1.3	12	1.9	174	28.3
Females	All cases		1369	32	2.4	4	0.3	8	0.6	61	4.5	24	1.8	26	1.9	423	31.4
	Age at baseline	<18	13	1	7.7	2	15.4
		18-19	11	5	45.5
		20-24	121	6	5.0	1	0.8	2	1.7	6	5.0	2	1.7	4	3.3	41	34.2
		25-29	332	7	2.1	1	0.3	1	0.3	18	5.5	4	1.2	5	1.5	141	42.9
		30-34	433	4	0.9	1	0.2	4	0.9	23	5.4	7	1.7	10	2.4	143	33.7
		35+	459	14	3.1	1	0.2	1	0.2	14	3.1	11	2.4	7	1.5	91	20.2
	Years since diagnosis	5-9	95	8	8.5	1	1.1	1	1.1	7	7.4	2	2.1	6	6.4	23	24.5
		10-14	426	7	1.7	2	0.5	3	0.7	21	5.0	5	1.2	4	1.0	175	41.7
		15-19	438	7	1.6	.	.	4	0.9	17	3.9	5	1.2	7	1.6	126	29.2
		20+	410	10	2.5	1	0.2	.	.	16	4.0	12	3.0	9	2.2	99	24.6
	Age at diagnosis	1-4	19	5	26.3
		5-9	94	1	1.1	3	3.2	3	3.2	1	1.1	34	36.2
		10-14	504	9	1.8	3	0.6	2	0.4	27	5.4	5	1.0	16	3.2	186	37.5
		15-20	752	22	3.0	1	0.1	6	0.8	31	4.2	16	2.2	9	1.2	198	26.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	551	19.8	29	1.0	34	1.2	926	33.4	1706	61.5	34	1.2	.	.
	Age at baseline	<18	55	19	35.8	1	1.8	.	.	23	43.4	30	56.6
		18-19	55	15	27.3	19	34.5	35	63.6
		20-24	328	91	28.3	6	1.9	3	0.9	124	38.6	223	69.5
		25-29	733	138	19.1	9	1.2	8	1.1	223	30.9	485	67.4	5	0.7	.	.
		30-34	862	156	18.4	9	1.1	14	1.6	271	32.1	530	62.7	14	1.6	.	.
		35+	794	132	16.9	4	0.5	9	1.1	266	34.1	403	51.8	15	1.9	.	.
	Years since diagnosis	5-9	221	76	35.3	3	1.4	5	2.3	95	43.8	137	63.1	3	1.4	.	.
		10-14	867	178	20.9	15	1.8	17	2.0	226	26.5	549	64.4	9	1.1	.	.
		15-19	930	129	14.1	11	1.2	8	0.9	311	34.2	561	61.7	11	1.2	.	.
		20+	809	168	21.0	.	.	4	0.5	294	37.0	459	57.8	11	1.4	.	.
	Age at diagnosis	1-4	71	15	21.4	29	41.4	43	61.4
		5-9	353	80	22.9	2	0.6	.	.	126	36.2	226	64.9
		10-14	1026	222	21.9	10	1.0	4	0.4	374	37.0	696	69.1	4	0.4	.	.
		15-20	1377	234	17.3	17	1.3	30	2.2	397	29.5	741	55.0	30	2.2	.	.
Males	All cases		1458	293	20.4	15	1.0	19	1.3	507	35.4	874	61.1	20	1.4	.	.
	Age at baseline	<18	42	15	37.5	1	2.4	.	.	15	37.5	22	55.0
		18-19	44	12	27.3	16	36.4	28	63.6
		20-24	207	56	27.7	3	1.5	2	1.0	79	39.3	138	68.7
		25-29	401	72	18.2	6	1.5	4	1.0	134	34.1	257	65.4	4	1.0	.	.
		30-34	429	86	20.2	4	0.9	8	1.9	143	33.6	258	60.8	10	2.3	.	.
		35+	335	52	15.7	1	0.3	5	1.5	120	36.5	171	52.0	6	1.8	.	.
	Years since diagnosis	5-9	126	44	35.8	2	1.6	2	1.6	60	48.8	79	64.2	2	1.6	.	.
		10-14	441	91	20.9	9	2.1	10	2.3	120	27.7	274	63.3	6	1.4	.	.
		15-19	492	70	14.4	4	0.8	4	0.8	174	36.1	295	61.3	5	1.0	.	.
		20+	399	88	22.2	.	.	3	0.8	153	38.8	226	57.4	7	1.8	.	.
	Age at diagnosis	1-4	52	13	25.5	21	41.2	32	62.7
		5-9	259	60	23.5	1	0.4	.	.	93	36.6	164	64.6
		10-14	522	121	23.4	6	1.2	2	0.4	201	39.1	336	65.5	3	0.6	.	.
		15-20	625	99	16.0	8	1.3	17	2.8	192	31.3	342	55.8	17	2.8	.	.
Females	All cases		1369	258	19.2	14	1.0	15	1.1	419	31.2	832	62.0	14	1.0	.	.
	Age at baseline	<18	13	4	30.8	8	61.5	8	61.5
		18-19	11	3	27.3	3	27.3	7	63.6
		20-24	121	35	29.2	3	2.5	1	0.8	45	37.5	85	70.8
		25-29	332	66	20.2	3	0.9	4	1.2	89	27.1	228	69.7	1	0.3	.	.
		30-34	433	70	16.6	5	1.2	6	1.4	128	30.5	272	64.6	4	0.9	.	.
		35+	459	80	17.7	3	0.7	4	0.9	146	32.4	232	51.7	9	2.0	.	.
	Years since diagnosis	5-9	95	32	34.8	1	1.1	3	3.2	35	37.2	58	61.7	1	1.1	.	.
		10-14	426	87	20.8	6	1.4	7	1.7	106	25.3	275	65.6	3	0.7	.	.
		15-19	438	59	13.8	7	1.6	4	0.9	137	32.0	266	62.1	6	1.4	.	.
		20+	410	80	19.9	.	.	1	0.2	141	35.2	233	58.3	4	1.0	.	.
	Age at diagnosis	1-4	19	2	10.5	8	42.1	11	57.9
		5-9	94	20	21.3	1	1.1	.	.	33	35.1	62	66.0
		10-14	504	101	20.3	4	0.8	2	0.4	173	34.9	360	72.9	1	0.2	.	.
		15-20	752	135	18.4	9	1.2	13	1.8	205	28.0	399	54.4	13	1.8	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
		All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases	1915	228	12.0	3	0.2	41	2.2	31	1.6	3	0.2	54	2.8	1678	88.8	
	Age at baseline	<18	200	24	12.1	6	3.0	.	.	4	2.0	182	92.4
		18-19	119	22	18.6	.	.	3	2.5	3	2.5	.	.	2	1.7	112	94.9
		20-24	405	39	9.7	1	0.2	9	2.2	8	2.0	.	.	12	3.0	360	89.6
		25-29	526	66	12.7	1	0.2	15	2.9	5	1.0	1	0.2	16	3.1	462	89.5
		30-34	438	52	11.9	1	0.2	13	3.0	8	1.8	1	0.2	15	3.4	380	87.2
		35+	227	25	11.2	.	.	1	0.4	1	0.4	1	0.4	5	2.2	182	82.4
	Years since diagnosis	5-9	132	20	15.2	.	.	1	0.8	3	2.3	.	.	5	3.8	117	89.3
		10-14	609	70	11.6	.	.	13	2.1	8	1.3	.	.	8	1.3	543	90.2
		15-19	657	80	12.3	3	0.5	22	3.4	13	2.0	1	0.2	29	4.4	579	89.1
		20+	517	58	11.4	.	.	5	1.0	7	1.4	2	0.4	12	2.3	439	86.6
	Age at diagnosis	<1	12	3	25.0	1	8.3	9	75.0
		1-4	315	38	12.2	1	0.3	3	1.0	8	2.6	1	0.3	12	3.8	283	92.2
		5-9	579	63	10.9	1	0.2	10	1.7	12	2.1	.	.	11	1.9	517	90.1
		10-14	602	82	13.7	1	0.2	20	3.3	6	1.0	1	0.2	17	2.8	542	90.6
		15-20	407	42	10.4	.	.	8	2.0	5	1.2	1	0.2	13	3.2	327	82.0
Males	All cases	1290	144	11.2	2	0.2	29	2.3	22	1.7	2	0.2	38	3.0	1135	89.0	
	Age at baseline	<18	138	12	8.8	5	3.6	.	.	3	2.2	126	93.3
		18-19	87	16	18.6	.	.	1	1.2	3	3.5	.	.	1	1.2	83	96.5
		20-24	264	26	9.8	1	0.4	7	2.7	4	1.5	.	.	8	3.0	236	89.7
		25-29	367	44	12.1	1	0.3	13	3.6	4	1.1	.	.	11	3.0	328	90.6
		30-34	286	32	11.2	.	.	8	2.8	5	1.8	1	0.4	11	3.9	246	86.6
		35+	148	14	9.6	1	0.7	1	0.7	4	2.7	116	80.0
	Years since diagnosis	5-9	99	12	12.1	.	.	1	1.0	2	2.0	.	.	3	3.0	90	91.8
		10-14	413	46	11.2	.	.	11	2.7	6	1.5	.	.	5	1.2	373	91.2
		15-19	426	50	11.8	2	0.5	13	3.1	9	2.1	1	0.2	20	4.7	376	88.9
		20+	352	36	10.4	.	.	4	1.1	5	1.4	1	0.3	10	2.9	296	85.8
	Age at diagnosis	<1	3	1	33.3
		1-4	211	26	12.5	1	0.5	2	1.0	6	2.9	.	.	10	4.8	188	91.7
		5-9	404	40	10.0	1	0.2	7	1.7	10	2.5	.	.	9	2.2	366	91.5
		10-14	409	56	13.7	.	.	14	3.4	3	0.7	1	0.2	11	2.7	371	90.7
		15-20	263	22	8.5	.	.	6	2.3	3	1.2	1	0.4	8	3.1	209	81.0
Females	All cases	625	84	13.5	1	0.2	12	1.9	9	1.5	1	0.2	16	2.6	543	88.3	
	Age at baseline	<18	62	12	19.4	1	1.6	.	.	1	1.6	56	90.3
		18-19	32	6	18.8	.	.	2	6.3	1	3.1	29	90.6
		20-24	141	13	9.3	.	.	2	1.4	4	2.9	.	.	4	2.9	124	89.2
		25-29	159	22	14.0	.	.	2	1.3	1	0.6	1	0.6	5	3.2	134	87.0
		30-34	152	20	13.2	1	0.7	5	3.3	3	2.0	.	.	4	2.6	134	88.2
		35+	79	11	14.3	.	.	1	1.3	1	1.3	66	86.8
	Years since diagnosis	5-9	33	8	24.2	1	3.0	.	.	2	6.1	27	81.8
		10-14	196	24	12.3	.	.	2	1.0	2	1.0	.	.	3	1.5	170	88.1
		15-19	231	30	13.2	1	0.4	9	3.9	4	1.8	.	.	9	3.9	203	89.4
		20+	165	22	13.4	.	.	1	0.6	2	1.2	1	0.6	2	1.2	143	88.3
	Age at diagnosis	<1	9	3	33.3	1	11.1	8	88.9
		1-4	104	12	11.7	.	.	1	1.0	2	1.9	1	1.0	2	1.9	95	93.1
		5-9	175	23	13.1	.	.	3	1.7	2	1.1	.	.	2	1.1	151	86.8
		10-14	193	26	13.6	1	0.5	6	3.1	3	1.6	.	.	6	3.1	171	90.5
		15-20	144	20	14.1	.	.	2	1.4	2	1.4	.	.	5	3.5	118	83.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1915	3	0.2	89	4.7	3	0.2	22	1.2	20	1.1	26	1.4	.	.
	Age at baseline	<18	200	.	.	5	2.5	1	0.5	3	1.5	.	.	2	1.0	.	.
		18-19	119	.	.	8	6.8	.	.	2	1.7	1	0.8	1	0.8	.	.
		20-24	405	1	0.2	19	4.7	1	0.2	6	1.5	3	0.7	6	1.5	.	.
		25-29	526	1	0.2	27	5.2	.	.	5	1.0	2	0.4	5	1.0	.	.
		30-34	438	1	0.2	26	5.9	.	.	5	1.1	9	2.1	10	2.3	.	.
		35+	227	.	.	4	1.8	1	0.4	1	0.4	5	2.3	2	0.9	.	.
	Years since diagnosis	5-9	132	.	.	3	2.3	1	0.8	2	1.5	2	1.5
		10-14	609	2	0.3	26	4.3	1	0.2	5	0.8	4	0.7	4	0.7	.	.
		15-19	657	1	0.2	52	8.0	1	0.2	9	1.4	9	1.4	17	2.6	.	.
		20+	517	.	.	8	1.6	.	.	6	1.2	5	1.0	5	1.0	.	.
	Age at diagnosis	<1	12
		1-4	315	.	.	18	5.8	.	.	5	1.6	1	0.3	5	1.6	.	.
		5-9	579	.	.	25	4.3	.	.	6	1.0	2	0.3	7	1.2	.	.
		10-14	602	2	0.3	24	4.0	2	0.3	9	1.5	6	1.0	6	1.0	.	.
		15-20	407	1	0.2	22	5.5	1	0.2	2	0.5	11	2.7	8	2.0	.	.
Males	All cases		1290	.	.	58	4.5	3	0.2	11	0.9	11	0.9	16	1.2	.	.
	Age at baseline	<18	138	.	.	3	2.2	1	0.7	2	1.5	.	.	1	0.7	.	.
		18-19	87	.	.	5	5.8	.	.	2	2.3	1	1.2
		20-24	264	.	.	13	4.9	1	0.4	2	0.8	1	0.4	4	1.5	.	.
		25-29	367	.	.	19	5.2	.	.	2	0.6	1	0.3	5	1.4	.	.
		30-34	286	.	.	16	5.6	.	.	2	0.7	4	1.4	5	1.8	.	.
		35+	148	.	.	2	1.4	1	0.7	1	0.7	4	2.7	1	0.7	.	.
	Years since diagnosis	5-9	99	.	.	1	1.0	1	1.0	1	1.0	1	1.0
		10-14	413	.	.	23	5.6	1	0.2	2	0.5	2	0.5	1	0.2	.	.
		15-19	426	.	.	28	6.6	1	0.2	6	1.4	5	1.2	10	2.4	.	.
		20+	352	.	.	6	1.7	.	.	2	0.6	3	0.9	5	1.4	.	.
	Age at diagnosis	<1	3
		1-4	211	.	.	13	6.2	.	.	4	1.9	.	.	3	1.4	.	.
		5-9	404	.	.	17	4.2	.	.	1	0.2	1	0.2	5	1.2	.	.
		10-14	409	.	.	15	3.7	2	0.5	5	1.2	3	0.7	5	1.2	.	.
		15-20	263	.	.	13	5.0	1	0.4	1	0.4	7	2.7	3	1.2	.	.
Females	All cases		625	3	0.5	31	5.0	.	.	11	1.8	9	1.5	10	1.6	.	.
	Age at baseline	<18	62	.	.	2	3.2	.	.	1	1.6	.	.	1	1.6	.	.
		18-19	32	.	.	3	9.4	1	3.1	.	.
		20-24	141	1	0.7	6	4.3	.	.	4	2.9	2	1.4	2	1.4	.	.
		25-29	159	1	0.6	8	5.1	.	.	3	1.9	1	0.6
		30-34	152	1	0.7	10	6.6	.	.	3	2.0	5	3.3	5	3.3	.	.
		35+	79	.	.	2	2.6	1	1.3	1	1.3	.	.
	Years since diagnosis	5-9	33	.	.	2	6.1	.	.	1	3.0	1	3.0
		10-14	196	2	1.0	3	1.5	.	.	3	1.5	2	1.0	3	1.5	.	.
		15-19	231	1	0.4	24	10.5	.	.	3	1.3	4	1.8	7	3.1	.	.
		20+	165	.	.	2	1.2	.	.	4	2.4	2	1.2
	Age at diagnosis	<1	9
		1-4	104	.	.	5	4.9	.	.	1	1.0	1	1.0	2	1.9	.	.
		5-9	175	.	.	8	4.6	.	.	5	2.9	1	0.6	2	1.1	.	.
		10-14	193	2	1.0	9	4.7	.	.	4	2.1	3	1.6	1	0.5	.	.
		15-20	144	1	0.7	9	6.3	.	.	1	0.7	4	2.8	5	3.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	2070	.	.	3	0.1	61	2.9	17	0.8	185	9.0	
	Age at baseline	<18	761	.	.	1	0.1	13	1.7	13	1.7	71	9.3
		18-19	275	15	5.5	28	10.2
		20-24	611	.	.	1	0.2	16	2.6	3	0.5	51	8.4
		25-29	342	.	.	1	0.3	16	4.7	1	0.3	27	7.9
		30-34	66	1	1.5	5	7.7
		35+	15	3	20.0
	Years since diagnosis	5-9	167	.	.	1	0.6	5	3.0	9	5.4	18	10.8
		10-14	675	15	2.2	6	0.9	74	11.0
		15-19	679	.	.	1	0.1	34	5.0	1	0.1	69	10.2
		20+	549	.	.	1	0.2	7	1.3	1	0.2	24	4.4
	Age at diagnosis	<1	301	4	1.3	2	0.7	15	5.0
		1-4	1261	27	2.1	9	0.7	94	7.5
		5-9	434	.	.	3	0.7	24	5.5	4	0.9	59	13.6
		10-14	54	4	7.5	1	1.9	12	23.1
		15-20	20	2	10.0	1	5.0	5	25.0
Males	All cases	917	.	.	2	0.2	30	3.3	7	0.8	81	8.8	
	Age at baseline	<18	369	.	.	1	0.3	8	2.2	7	1.9	40	10.8
		18-19	111	7	6.3	12	10.8
		20-24	252	4	1.6	14	5.6
		25-29	152	.	.	1	0.7	11	7.2	13	8.6
		30-34	27	1	3.7
		35+	6	1	16.7
	Years since diagnosis	5-9	74	.	.	1	1.4	3	4.1	4	5.4	12	16.2
		10-14	307	4	1.3	3	1.0	31	10.1
		15-19	289	16	5.5	27	9.3
		20+	247	.	.	1	0.4	7	2.8	11	4.5
	Age at diagnosis	<1	149	3	2.0	7	4.7
		1-4	564	13	2.3	4	0.7	44	7.8
		5-9	177	.	.	2	1.1	14	7.9	2	1.1	23	13.0
		10-14	19	1	5.3	5	26.3
		15-20	8	2	25.0
Females	All cases	1153	.	.	1	0.1	31	2.7	10	0.9	104	9.0	
	Age at baseline	<18	392	5	1.3	6	1.5	31	7.9
		18-19	164	8	4.9	16	9.8
		20-24	359	.	.	1	0.3	12	3.3	3	0.8	37	10.3
		25-29	190	5	2.6	1	0.5	14	7.4
		30-34	39	1	2.6	4	10.5
		35+	9	2	22.2
	Years since diagnosis	5-9	93	2	2.2	5	5.4	6	6.5
		10-14	368	11	3.0	3	0.8	43	11.7
		15-19	390	.	.	1	0.3	18	4.6	1	0.3	42	10.8
		20+	302	1	0.3	13	4.3
	Age at diagnosis	<1	152	1	0.7	2	1.3	8	5.3
		1-4	697	14	2.0	5	0.7	50	7.2
		5-9	257	.	.	1	0.4	10	3.9	2	0.8	36	14.0
		10-14	35	4	11.8	7	21.2
		15-20	12	2	16.7	1	8.3	3	25.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	2070	2	0.1	62	3.0	4	0.2	1	0.0	.	.	8	0.4	.	.	
	Age at baseline	<18	761	.	23	3.0	1	0.1	2	0.3	.	.	
		18-19	275	.	8	2.9	
		20-24	611	2	0.3	15	2.5	2	0.3	1	0.2	.	.	4	0.7	.	
		25-29	342	.	14	4.1	1	0.3	2	0.6	.	.	
		30-34	66	.	1	1.5	
		35+	15	.	1	6.7	
	Years since diagnosis	5-9	167	1	0.6	13	7.8	1	0.6	1	0.6	.	
		10-14	675	.	17	2.5	1	0.1	1	0.1	.	.	
		15-19	679	1	0.1	17	2.5	2	0.3	1	0.1	.	.	5	0.7	.	
		20+	549	.	15	2.7	1	0.2	.	.	
	Age at diagnosis	<1	301	.	5	1.7	1	0.3	.	.	
		1-4	1261	.	34	2.7	.	.	1	0.1	.	.	3	0.2	.	.	
		5-9	434	1	0.2	16	3.7	4	0.9	.	.	.	4	0.9	.	.	
		10-14	54	.	3	5.7	
		15-20	20	1	5.0	4	20.0	
Males	All cases	917	1	0.1	28	3.1	2	0.2	2	0.2	.	.	
	Age at baseline	<18	369	.	13	3.5	1	0.3	1	0.3	.	.	
		18-19	111	.	4	3.6	
		20-24	252	1	0.4	5	2.0	
		25-29	152	.	6	3.9	1	0.7	1	0.7	.	.	
		30-34	27	
		35+	6	
	Years since diagnosis	5-9	74	.	6	8.1	1	1.4	1	1.4	.	.	
		10-14	307	.	7	2.3	
		15-19	289	1	0.3	8	2.8	1	0.3	.	.	.	1	0.3	.	.	
		20+	247	.	7	2.8	
	Age at diagnosis	<1	149	.	4	2.7	
		1-4	564	.	16	2.8	1	0.2	.	.	
		5-9	177	1	0.6	7	4.0	2	1.1	.	.	.	1	0.6	.	.	
		10-14	19	
		15-20	8	.	1	12.5	
Females	All cases	1153	1	0.1	34	3.0	2	0.2	1	0.1	.	.	6	0.5	.	.	
	Age at baseline	<18	392	.	10	2.6	1	0.3	.	.	
		18-19	164	.	4	2.4	
		20-24	359	1	0.3	10	2.8	2	0.6	1	0.3	.	.	4	1.1	.	
		25-29	190	.	8	4.2	1	0.5	.	.	
		30-34	39	.	1	2.6	
		35+	9	.	1	11.1	
	Years since diagnosis	5-9	93	1	1.1	7	7.5	
		10-14	368	.	10	2.7	1	0.3	1	0.3	.	.	
		15-19	390	.	9	2.3	1	0.3	1	0.3	.	.	4	1.0	.	.	
		20+	302	.	8	2.6	1	0.3	.	.	
	Age at diagnosis	<1	152	.	1	0.7	1	0.7	.	.	
		1-4	697	.	18	2.6	.	.	1	0.1	.	.	2	0.3	.	.	
		5-9	257	.	9	3.5	2	0.8	3	1.2	.	.	
		10-14	35	.	3	8.8	
		15-20	12	1	8.3	3	25.0	

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Neuroblastoma

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1798	3	0.2	1	0.1	244	13.7	1	0.1	.	.	504	28.3	1039	58.7
	Age at baseline	<18	889	1	0.1	.	.	157	17.8	1	0.1	.	.	242	27.4	516	58.9
		18-19	216	21	9.7	56	26.2	122	56.7
		20-24	504	2	0.4	1	0.2	54	10.8	159	31.8	298	59.8
		25-29	150	11	7.5	37	25.3	79	54.9
		30-34	34	1	3.1	9	28.1	22	68.8
		35+	5	1	20.0	2	40.0
	Years since diagnosis	5-9	152	33	22.0	74	49.3	107	71.3
		10-14	558	104	18.6	1	0.2	.	.	137	24.7	314	56.6
		15-19	594	1	0.2	1	0.2	75	12.8	164	27.9	329	56.5
		20+	494	2	0.4	.	.	32	6.6	129	26.5	289	59.8
	Age at diagnosis	<1	912	1	0.1	.	.	72	7.9	1	0.1	.	.	159	17.5	497	55.3
		1-4	706	2	0.3	1	0.1	136	19.5	275	39.5	435	62.5
		5-9	137	29	21.5	54	40.6	84	63.2
		10-14	27	3	11.5	8	30.8	14	53.8
		15-20	16	4	25.0	8	50.0	9	56.3
Males	All cases		870	.	.	1	0.1	134	15.5	254	29.5	515	60.1
	Age at baseline	<18	440	93	21.3	121	27.8	265	61.2
		18-19	94	10	10.6	28	29.8	57	60.6
		20-24	255	.	.	1	0.4	27	10.7	80	31.7	139	55.4
		25-29	65	4	6.3	20	31.3	41	65.1
		30-34	14	4	28.6	12	85.7
		35+	2	1	50.0	1	50.0
	Years since diagnosis	5-9	72	15	21.1	36	50.7	50	70.4
		10-14	274	64	23.4	69	25.3	163	59.9
		15-19	283	.	.	1	0.4	41	14.6	82	29.3	161	58.1
		20+	241	14	5.9	67	28.2	141	59.5
	Age at diagnosis	<1	470	41	8.8	76	16.2	253	54.5
		1-4	317	.	.	1	0.3	74	23.6	137	43.9	205	65.7
		5-9	67	18	27.3	34	51.5	48	73.8
		10-14	10	1	10.0	3	30.0	5	50.0
		15-20	6	4	66.7	4	66.7
Females	All cases		928	3	0.3	.	.	110	12.0	1	0.1	.	.	250	27.3	524	57.4
	Age at baseline	<18	449	1	0.2	.	.	64	14.3	1	0.2	.	.	121	27.1	251	56.7
		18-19	122	11	9.0	28	23.3	65	53.7
		20-24	249	2	0.8	.	.	27	10.9	79	31.9	159	64.4
		25-29	85	7	8.4	17	20.7	38	46.9
		30-34	20	1	5.6	5	27.8	10	55.6
		35+	3	1	33.3
	Years since diagnosis	5-9	80	18	22.8	38	48.1	57	72.2
		10-14	284	40	14.1	1	0.4	.	.	68	24.1	151	53.4
		15-19	311	1	0.3	.	.	34	11.0	82	26.6	168	55.1
		20+	253	2	0.8	.	.	18	7.2	62	25.0	148	60.2
	Age at diagnosis	<1	442	1	0.2	.	.	31	7.1	1	0.2	.	.	83	18.9	244	56.1
		1-4	389	2	0.5	.	.	62	16.1	138	35.8	230	59.9
		5-9	70	11	15.9	20	29.9	36	52.9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Neuroblastoma

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1798	187	10.5	126	7.1	128	7.2	49	2.7	6	0.3	28	1.6	3	0.2
	Age at baseline	<18	889	99	11.2	64	7.2	79	8.9	18	2.0	3	0.3	15	1.7	3	0.3
		18-19	216	20	9.3	15	7.0	9	4.2	5	2.3	.	.	3	1.4	.	.
		20-24	504	47	9.4	40	8.0	28	5.6	16	3.2	1	0.2	7	1.4	.	.
		25-29	150	14	9.6	6	4.1	10	6.8	8	5.4	1	0.7	2	1.4	.	.
		30-34	34	7	21.9	.	.	2	6.3	2	6.3	1	3.1	1	3.1	.	.
		35+	5	.	.	1	20.0
	Years since diagnosis	5-9	152	25	16.8	20	13.3	25	16.7	8	5.3	.	.	5	3.3	2	1.3
		10-14	558	58	10.4	32	5.7	54	9.7	9	1.6	3	0.5	9	1.6	1	0.2
		15-19	594	59	10.0	51	8.7	27	4.6	11	1.9	.	.	9	1.5	.	.
		20+	494	45	9.3	23	4.7	22	4.5	21	4.3	3	0.6	5	1.0	.	.
	Age at diagnosis	<1	912	79	8.7	23	2.5	16	1.8	21	2.3	2	0.2	2	0.2	.	.
		1-4	706	85	12.2	79	11.3	86	12.3	22	3.1	3	0.4	21	3.0	3	0.4
		5-9	137	18	13.3	20	14.9	23	17.0	3	2.2	1	0.7	3	2.2	.	.
		10-14	27	3	11.5	2	7.7	2	7.7	2	7.7
		15-20	16	2	12.5	2	12.5	1	6.3	1	6.3	.	.	2	12.5	.	.
Males	All cases		870	89	10.3	70	8.1	64	7.4	25	2.9	1	0.1	13	1.5	2	0.2
	Age at baseline	<18	440	42	9.6	41	9.4	40	9.1	8	1.8	.	.	6	1.4	2	0.5
		18-19	94	13	13.8	9	9.6	6	6.4	3	3.2	.	.	2	2.1	.	.
		20-24	255	24	9.5	18	7.1	13	5.2	11	4.4	.	.	3	1.2	.	.
		25-29	65	6	9.4	1	1.6	4	6.3	3	4.7	.	.	2	3.1	.	.
		30-34	14	4	28.6	.	.	1	7.1	.	.	1	7.1
		35+	2	.	.	1	50.0
	Years since diagnosis	5-9	72	7	10.0	10	14.1	10	14.1	2	2.8	.	.	1	1.4	2	2.8
		10-14	274	27	9.9	19	6.9	30	10.9	4	1.5	.	.	5	1.8	.	.
		15-19	283	31	11.0	32	11.4	14	5.0	8	2.8	.	.	6	2.1	.	.
		20+	241	24	10.1	9	3.8	10	4.2	11	4.6	1	0.4	1	0.4	.	.
	Age at diagnosis	<1	470	37	7.9	13	2.8	8	1.7	9	1.9
		1-4	317	40	12.8	43	13.7	43	13.7	14	4.5	.	.	9	2.9	2	0.6
		5-9	67	11	16.7	13	19.7	12	18.2	2	3.0	1	1.5	3	4.5	.	.
		10-14	10	1	10.0
		15-20	6	1	16.7	1	16.7	1	16.7	.	.
Females	All cases		928	98	10.7	56	6.1	64	7.0	24	2.6	5	0.5	15	1.6	1	0.1
	Age at baseline	<18	449	57	12.8	23	5.2	39	8.7	10	2.2	3	0.7	9	2.0	1	0.2
		18-19	122	7	5.7	6	5.0	3	2.5	2	1.6	.	.	1	0.8	.	.
		20-24	249	23	9.3	22	8.9	15	6.0	5	2.0	1	0.4	4	1.6	.	.
		25-29	85	8	9.8	5	6.1	6	7.2	5	6.0	1	1.2
		30-34	20	3	16.7	.	.	1	5.6	2	11.1	.	.	1	5.6	.	.
		35+	3
	Years since diagnosis	5-9	80	18	22.8	10	12.7	15	19.0	6	7.6	.	.	4	5.1	.	.
		10-14	284	31	10.9	13	4.6	24	8.5	5	1.8	3	1.1	4	1.4	1	0.4
		15-19	311	28	9.1	19	6.2	13	4.2	3	1.0	.	.	3	1.0	.	.
		20+	253	21	8.5	14	5.6	12	4.8	10	4.0	2	0.8	4	1.6	.	.
	Age at diagnosis	<1	442	42	9.6	10	2.3	8	1.8	12	2.7	2	0.5	2	0.5	.	.
		1-4	389	45	11.7	36	9.4	43	11.1	8	2.1	3	0.8	12	3.1	1	0.3
		5-9	70	7	10.1	7	10.3	11	15.9	1	1.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Neuroblastoma

				BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	2	12.5	5	31.3	9	56.3
		15-20	10	4	40.0	4	40.0	5	50.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Neuroblastoma

				DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	3	18.8	2	12.5	1	6.3	2	12.5
		15-20	10	1	10.0	1	10.0	1	10.0	1	10.0	.	.	1	10.0	.	.

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	13	0.8	2	0.1	23	1.5	1	0.1	10	0.6	133	8.4	1075	68.6
	Age at baseline	<18	313	.	.	1	0.3	10	3.2	1	0.3	2	0.6	58	18.6	240	77.7
		18-19	115	2	1.8	1	0.9	3	2.6	8	7.0	90	78.9
		20-24	382	2	0.5	.	.	3	0.8	.	.	2	0.5	27	7.1	276	73.0
		25-29	351	3	0.9	.	.	4	1.1	.	.	3	0.9	24	6.9	234	67.6
		30-34	264	3	1.1	.	.	3	1.1	.	.	1	0.4	11	4.2	161	61.5
		35+	163	3	1.9	2	1.3	5	3.1	74	46.5
	Years since diagnosis	5-9	165	5	3.0	.	.	1	0.6	48	29.4	111	68.9
		10-14	473	1	0.2	1	0.2	6	1.3	1	0.2	2	0.4	46	9.8	328	70.1
		15-19	498	7	1.4	1	0.2	7	1.4	.	.	3	0.6	12	2.4	365	73.9
		20+	452	5	1.1	.	.	5	1.1	.	.	4	0.9	27	6.1	271	60.9
	Age at diagnosis	<1	108	2	1.9	5	4.7	63	58.9
		1-4	507	3	0.6	2	0.4	12	2.4	1	0.2	4	0.8	61	12.1	400	79.8
		5-9	361	3	0.8	.	.	6	1.7	.	.	3	0.8	28	7.8	260	72.4
		10-14	311	3	1.0	.	.	3	1.0	.	.	1	0.3	22	7.2	200	65.8
		15-20	301	4	1.3	2	0.7	17	5.7	152	51.2
Males	All cases		847	10	1.2	1	0.1	14	1.7	.	.	6	0.7	81	9.6	584	69.8
	Age at baseline	<18	179	.	.	1	0.6	7	3.9	.	.	2	1.1	36	20.1	147	83.1
		18-19	58	2	3.4	4	6.9	47	81.0
		20-24	213	1	0.5	.	.	1	0.5	.	.	2	0.9	16	7.5	148	70.5
		25-29	179	3	1.7	.	.	4	2.2	.	.	1	0.6	12	6.8	121	68.4
		30-34	139	2	1.4	.	.	2	1.4	8	5.8	85	62.0
		35+	79	2	2.6	1	1.3	5	6.4	36	46.2
	Years since diagnosis	5-9	89	2	2.2	.	.	1	1.1	29	33.0	63	73.3
		10-14	264	1	0.4	1	0.4	6	2.3	.	.	2	0.8	29	11.0	193	73.7
		15-19	252	5	2.0	.	.	2	0.8	.	.	1	0.4	8	3.2	180	72.3
		20+	242	4	1.7	.	.	4	1.7	.	.	2	0.8	15	6.3	148	61.7
	Age at diagnosis	<1	44	1	2.3	2	4.5	30	68.2
		1-4	293	3	1.0	1	0.3	8	2.7	.	.	4	1.4	37	12.7	233	80.3
		5-9	202	2	1.0	.	.	2	1.0	17	8.5	143	71.5
		10-14	167	3	1.8	.	.	3	1.8	.	.	1	0.6	14	8.5	106	65.0
		15-20	141	2	1.4	1	0.7	11	7.9	72	51.4
Females	All cases		741	3	0.4	1	0.1	9	1.2	1	0.1	4	0.5	52	7.1	491	67.2
	Age at baseline	<18	134	3	2.3	1	0.8	.	.	22	16.5	93	70.5
		18-19	57	.	.	1	1.8	3	5.4	4	7.1	43	76.8
		20-24	169	1	0.6	.	.	2	1.2	11	6.5	128	76.2
		25-29	172	2	1.2	12	7.1	113	66.9
		30-34	125	1	0.8	.	.	1	0.8	.	.	1	0.8	3	2.4	76	60.8
		35+	84	1	1.2	1	1.2	.	.	38	46.9
	Years since diagnosis	5-9	76	3	4.0	19	25.3	48	64.0
		10-14	209	1	0.5	.	.	17	8.2	135	65.5
		15-19	246	2	0.8	1	0.4	5	2.0	.	.	2	0.8	4	1.6	185	75.5
		20+	210	1	0.5	.	.	1	0.5	.	.	2	1.0	12	5.8	123	60.0
	Age at diagnosis	<1	64	1	1.6	3	4.8	33	52.4
		1-4	214	.	.	1	0.5	4	1.9	1	0.5	.	.	24	11.3	167	79.1
		5-9	159	1	0.6	.	.	4	2.5	.	.	3	1.9	11	6.9	117	73.6
		10-14	144	8	5.6	94	66.7
		15-20	160	2	1.3	1	0.6	6	3.8	80	51.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	79	5.0	256	16.2	24	1.5	14	0.9	1	0.1	8	0.5		
	Age at baseline	<18	313	24	7.7	55	17.6	7	2.2	6	1.9	1	0.3	1	0.3		
		18-19	115	3	2.6	20	17.5	3	2.6					1	0.9		
		20-24	382	11	2.9	89	23.4	8	2.1	2	0.5			3	0.8		
		25-29	351	13	3.7	54	15.5	3	0.9	2	0.6			2	0.6		
		30-34	264	11	4.2	31	11.8	1	0.4	3	1.1			1	0.4		
		35+	163	17	10.6	7	4.4	2	1.3	1	0.6						
	Years since diagnosis	5-9	165	20	12.3	24	14.6	5	3.0	2	1.2						
		10-14	473	26	5.5	69	14.6	6	1.3	5	1.1	1	0.2	2	0.4		
		15-19	498	21	4.2	105	21.2	8	1.6	5	1.0			4	0.8		
		20+	452	12	2.7	58	13.0	5	1.1	2	0.4			2	0.4		
	Age at diagnosis	<1	108	3	2.8	16	15.0	2	1.9								
		1-4	507	23	4.6	106	21.1	11	2.2	9	1.8	1	0.2	4	0.8		
		5-9	361	8	2.2	66	18.3	4	1.1					1	0.3		
		10-14	311	17	5.5	42	13.7	3	1.0	2	0.7			3	1.0		
		15-20	301	28	9.4	26	8.7	4	1.3	3	1.0						
Males	All cases		847	44	5.2	147	17.5	12	1.4	10	1.2			6	0.7		
	Age at baseline	<18	179	16	9.0	38	21.2	5	2.8	3	1.7			1	0.6		
		18-19	58	1	1.7	9	15.5										
		20-24	213	5	2.4	47	22.2	5	2.4	1	0.5			2	0.9		
		25-29	179	5	2.8	33	18.5	1	0.6	2	1.1			2	1.1		
		30-34	139	8	5.8	18	13.1			3	2.2			1	0.7		
		35+	79	9	11.5	2	2.6	1	1.3	1	1.3						
	Years since diagnosis	5-9	89	11	12.6	16	18.0	2	2.2	2	2.2						
		10-14	264	13	4.9	48	18.2	5	1.9	3	1.1			2	0.8		
		15-19	252	12	4.8	54	21.6	3	1.2	3	1.2			2	0.8		
		20+	242	8	3.3	29	12.1	2	0.8	2	0.8			2	0.8		
	Age at diagnosis	<1	44	1	2.3	7	15.9	1	2.3								
		1-4	293	16	5.5	59	20.3	7	2.4	5	1.7			3	1.0		
		5-9	202	4	2.0	42	20.9										
		10-14	167	9	5.5	30	18.2	3	1.8	2	1.2			3	1.8		
		15-20	141	14	10.0	9	6.4	1	0.7	3	2.1						
Females	All cases		741	35	4.8	109	14.9	12	1.6	4	0.5	1	0.1	2	0.3		
	Age at baseline	<18	134	8	6.0	17	12.8	2	1.5	3	2.3	1	0.8				
		18-19	57	2	3.6	11	19.6	3	5.4					1	1.8		
		20-24	169	6	3.6	42	25.0	3	1.8	1	0.6			1	0.6		
		25-29	172	8	4.7	21	12.4	2	1.2								
		30-34	125	3	2.4	13	10.4	1	0.8								
		35+	84	8	9.8	5	6.1	1	1.2								
	Years since diagnosis	5-9	76	9	12.0	8	10.7	3	4.0								
		10-14	209	13	6.3	21	10.1	1	0.5	2	1.0	1	0.5				
		15-19	246	9	3.7	51	20.7	5	2.0	2	0.8			2	0.8		
		20+	210	4	1.9	29	14.1	3	1.5								
	Age at diagnosis	<1	64	2	3.2	9	14.3	1	1.6								
		1-4	214	7	3.3	47	22.2	4	1.9	4	1.9	1	0.5	1	0.5		
		5-9	159	4	2.5	24	15.1	4	2.5					1	0.6		
		10-14	144	8	5.6	12	8.5										
		15-20	160	14	8.9	17	10.8	3	1.9								

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	1931	20	1.0	7	0.4	87	4.5	2	0.1	7	0.4	642	33.5	1164	60.8	
	Age at baseline	<18	85	1	1.2	.	.	5	6.0	22	25.9	67	79.8
		18-19	66	4	6.1	20	30.3	49	74.2
		20-24	359	4	1.1	3	0.8	22	6.2	1	0.3	2	0.6	136	38.1	258	72.1
		25-29	528	4	0.8	2	0.4	27	5.1	.	.	1	0.2	204	38.9	302	57.9
		30-34	517	6	1.2	1	0.2	19	3.7	1	0.2	1	0.2	170	33.1	277	54.1
		35+	376	5	1.3	1	0.3	10	2.7	.	.	3	0.8	90	24.2	211	56.9
	Years since diagnosis	5-9	214	2	0.9	.	.	18	8.5	.	.	2	0.9	102	48.1	155	72.8
		10-14	629	3	0.5	2	0.3	36	5.7	245	39.3	389	62.4
		15-19	633	10	1.6	5	0.8	24	3.8	2	0.3	2	0.3	181	28.7	352	56.2
		20+	455	5	1.1	.	.	9	2.0	.	.	3	0.7	114	25.2	268	59.4
	Age at diagnosis	<1	8	1	12.5	5	62.5
		1-4	80	1	1.3	19	23.8	61	77.2
		5-9	338	5	1.5	3	0.9	14	4.1	1	0.3	1	0.3	80	23.7	229	67.8
		10-14	774	8	1.0	2	0.3	40	5.2	1	0.1	3	0.4	291	37.8	459	60.1
		15-20	731	6	0.8	2	0.3	32	4.4	.	.	3	0.4	252	34.9	410	56.6
Males	All cases	978	13	1.3	4	0.4	43	4.4	1	0.1	3	0.3	329	33.8	602	62.0	
	Age at baseline	<18	43	1	2.3	.	.	1	2.4	14	32.6	32	74.4
		18-19	33	2	6.1	8	24.2	22	66.7
		20-24	174	2	1.2	1	0.6	13	7.5	.	.	2	1.2	63	36.4	128	74.0
		25-29	274	2	0.7	2	0.7	13	4.8	112	41.2	155	57.0
		30-34	255	4	1.6	.	.	7	2.8	1	0.4	.	.	85	33.6	149	58.9
		35+	199	4	2.0	1	0.5	7	3.5	.	.	1	0.5	47	23.7	116	58.9
	Years since diagnosis	5-9	114	1	0.9	.	.	9	8.0	.	.	2	1.8	54	47.8	80	70.8
		10-14	318	.	.	1	0.3	16	5.0	128	40.6	197	62.3
		15-19	320	8	2.5	3	0.9	14	4.4	1	0.3	.	.	90	28.2	184	57.9
		20+	226	4	1.8	.	.	4	1.8	.	.	1	0.4	57	25.3	141	62.9
	Age at diagnosis	<1	4	3	75.0
		1-4	41	1	2.4	10	24.4	33	80.5
		5-9	173	4	2.3	2	1.2	7	4.0	38	22.0	118	68.2
		10-14	362	3	0.8	1	0.3	17	4.7	1	0.3	1	0.3	134	37.2	218	60.9
		15-20	398	5	1.3	1	0.3	19	4.8	.	.	2	0.5	147	37.3	230	58.2
Females	All cases	953	7	0.7	3	0.3	44	4.6	1	0.1	4	0.4	313	33.1	562	59.7	
	Age at baseline	<18	42	4	9.5	8	19.0	35	85.4
		18-19	33	2	6.1	12	36.4	27	81.8
		20-24	185	2	1.1	2	1.1	9	4.9	1	0.5	.	.	73	39.7	130	70.3
		25-29	254	2	0.8	.	.	14	5.5	.	.	1	0.4	92	36.5	147	58.8
		30-34	262	2	0.8	1	0.4	12	4.6	.	.	1	0.4	85	32.6	128	49.4
		35+	177	1	0.6	.	.	3	1.7	.	.	2	1.1	43	24.7	95	54.6
	Years since diagnosis	5-9	100	1	1.0	.	.	9	9.1	48	48.5	75	75.0
		10-14	311	3	1.0	1	0.3	20	6.4	117	37.9	192	62.5
		15-19	313	2	0.6	2	0.6	10	3.2	1	0.3	2	0.6	91	29.3	168	54.5
		20+	229	1	0.4	.	.	5	2.2	.	.	2	0.9	57	25.1	127	55.9
	Age at diagnosis	<1	4	1	25.0	2	50.0
		1-4	39	9	23.1	28	73.7
		5-9	165	1	0.6	1	0.6	7	4.2	1	0.6	1	0.6	42	25.5	111	67.3
		10-14	412	5	1.2	1	0.2	23	5.6	.	.	2	0.5	157	38.4	241	59.4
		15-20	333	1	0.3	1	0.3	13	4.0	.	.	1	0.3	105	31.9	180	54.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1931	44	2.3	590	30.7	68	3.5	8	0.4	.	.	9	0.5	1	0.1
	Age at baseline	<18	85	1	1.2	37	43.5	2	2.4	1	1.2	.	.	1	1.2	.	.
		18-19	66	1	1.5	21	31.8	1	1.5	1	1.5	1	1.5
		20-24	359	8	2.2	129	36.2	9	2.5	1	0.3	.	.	4	1.1	.	.
		25-29	528	10	1.9	180	34.2	10	1.9	2	0.4	.	.	1	0.2	.	.
		30-34	517	14	2.7	148	28.8	23	4.5	1	0.2	.	.	1	0.2	.	.
		35+	376	10	2.7	75	20.2	23	6.2	3	0.8	.	.	1	0.3	.	.
	Years since diagnosis	5-9	214	12	5.7	68	32.1	3	1.4	2	0.9	.	.	1	0.5	1	0.5
		10-14	629	16	2.6	210	33.5	13	2.1	1	0.2	.	.	4	0.6	.	.
		15-19	633	9	1.4	209	33.3	27	4.3	2	0.3	.	.	4	0.6	.	.
		20+	455	7	1.5	103	22.8	25	5.5	3	0.7
	Age at diagnosis	<1	8	.	.	4	50.0	1	12.5
		1-4	80	1	1.3	30	37.5	.	.	1	1.3	.	.	2	2.5	.	.
		5-9	338	1	0.3	118	34.9	13	3.8	1	0.3	.	.	1	0.3	.	.
		10-14	774	2	0.3	248	32.3	27	3.5	4	0.5	.	.	3	0.4	1	0.1
		15-20	731	40	5.5	190	26.2	27	3.7	2	0.3	.	.	3	0.4	.	.
Males	All cases		978	24	2.5	305	31.3	30	3.1	3	0.3	.	.	4	0.4	.	.
	Age at baseline	<18	43	.	.	19	44.2	1	2.4	.	.
		18-19	33	.	.	9	27.3
		20-24	174	4	2.3	64	37.2	4	2.3	1	0.6	.	.
		25-29	274	6	2.2	97	35.5	6	2.2	1	0.4	.	.	1	0.4	.	.
		30-34	255	7	2.8	74	29.1	9	3.5	1	0.4
		35+	199	7	3.5	42	21.2	11	5.6	1	0.5	.	.	1	0.5	.	.
	Years since diagnosis	5-9	114	7	6.3	41	36.3	1	0.9	1	0.9	.	.
		10-14	318	7	2.2	98	31.0	5	1.6	2	0.6	.	.
		15-19	320	5	1.6	110	34.5	15	4.7	1	0.3	.	.	1	0.3	.	.
		20+	226	5	2.2	56	24.9	9	4.0	2	0.9
	Age at diagnosis	<1	4	.	.	2	50.0
		1-4	41	.	.	16	39.0	1	2.4	.	.
		5-9	173	.	.	58	33.5	5	2.9	1	0.6
		10-14	362	.	.	122	34.0	11	3.1	2	0.6	.	.	1	0.3	.	.
		15-20	398	24	6.1	107	27.0	14	3.5	2	0.5	.	.
Females	All cases		953	20	2.1	285	30.1	38	4.0	5	0.5	.	.	5	0.5	1	0.1
	Age at baseline	<18	42	1	2.4	18	42.9	2	4.8	1	2.4
		18-19	33	1	3.0	12	36.4	1	3.0	1	3.0	1	3.0
		20-24	185	4	2.2	65	35.3	5	2.7	1	0.5	.	.	3	1.6	.	.
		25-29	254	4	1.6	83	32.8	4	1.6	1	0.4
		30-34	262	7	2.7	74	28.5	14	5.4	1	0.4	.	.
		35+	177	3	1.7	33	19.0	12	6.9	2	1.1
	Years since diagnosis	5-9	100	5	5.0	27	27.3	2	2.0	2	2.0	1	1.0
		10-14	311	9	2.9	112	36.0	8	2.6	1	0.3	.	.	2	0.6	.	.
		15-19	313	4	1.3	99	32.0	12	3.9	1	0.3	.	.	3	1.0	.	.
		20+	229	2	0.9	47	20.7	16	7.0	1	0.4
	Age at diagnosis	<1	4	.	.	2	50.0	1	25.0
		1-4	39	1	2.6	14	35.9	.	.	1	2.6	.	.	1	2.6	.	.
		5-9	165	1	0.6	60	36.4	8	4.8	1	0.6	.	.
		10-14	412	2	0.5	126	30.8	16	3.9	2	0.5	.	.	2	0.5	1	0.2
		15-20	333	16	4.8	83	25.2	13	3.9	2	0.6	.	.	1	0.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		685	19	2.8	5	0.7	13	1.9	2	0.3	7	1.0	24	3.5	639	94.5
	Age at baseline	<18	54	1	1.9	.	.	4	7.5	2	3.7	48	90.6
		18-19	33	1	3.0	1	3.0	31	93.9
		20-24	157	4	2.6	2	1.3	.	.	1	0.6	2	1.3	13	8.3	148	94.9
		25-29	193	4	2.1	2	1.0	6	3.1	.	.	1	0.5	6	3.1	183	95.8
		30-34	153	6	3.9	1	0.7	2	1.3	1	0.7	1	0.7	2	1.3	143	96.0
		35+	95	4	4.2	3	3.2	.	.	86	91.5
	Years since diagnosis	5-9	90	2	2.2	.	.	4	4.5	.	.	2	2.2	13	14.6	79	88.8
		10-14	231	3	1.3	2	0.9	6	2.6	9	3.9	222	96.9
		15-19	214	10	4.7	3	1.4	2	0.9	2	0.9	2	0.9	1	0.5	202	96.7
		20+	150	4	2.7	.	.	1	0.7	.	.	3	2.0	1	0.7	136	91.3
	Age at diagnosis	<1	4	1	25.0	2	50.0
		1-4	50	1	2.0	2	4.0	45	91.8
		5-9	170	5	2.9	2	1.2	2	1.2	1	0.6	1	0.6	2	1.2	164	96.5
		10-14	257	7	2.7	2	0.8	8	3.1	1	0.4	3	1.2	7	2.7	236	93.7
		15-20	204	6	3.0	1	0.5	2	1.0	.	.	3	1.5	13	6.4	192	95.5
Males	All cases		353	12	3.4	2	0.6	5	1.4	1	0.3	3	0.9	15	4.3	334	95.4
	Age at baseline	<18	24	1	4.2	1	4.2	22	91.7
		18-19	17	1	5.9	16	94.1
		20-24	78	2	2.6	2	2.6	9	11.7	76	98.7
		25-29	99	2	2.0	2	2.0	3	3.0	4	4.0	93	93.9
		30-34	83	4	4.8	.	.	1	1.2	1	1.2	.	.	1	1.2	79	96.3
		35+	52	3	5.8	1	1.9	.	.	48	94.1
	Years since diagnosis	5-9	48	1	2.1	.	.	1	2.2	.	.	2	4.3	9	19.1	43	91.5
		10-14	109	.	.	1	0.9	2	1.8	4	3.7	106	97.2
		15-19	115	8	7.0	1	0.9	2	1.7	1	0.9	.	.	1	0.9	109	95.6
		20+	81	3	3.7	1	1.2	1	1.2	76	95.0
	Age at diagnosis	<1	2	1	50.0
		1-4	26	1	3.8	2	7.7	26	.
		5-9	84	4	4.8	1	1.2	1	1.2	82	97.6
		10-14	135	2	1.5	1	0.7	4	3.0	1	0.7	1	0.7	5	3.7	125	94.0
		15-20	106	5	4.7	.	.	1	0.9	.	.	2	1.9	7	6.6	100	95.2
Females	All cases		332	7	2.1	3	0.9	8	2.4	1	0.3	4	1.2	9	2.7	305	93.6
	Age at baseline	<18	30	4	13.3	1	3.3	26	89.7
		18-19	16	1	6.3	15	93.8
		20-24	79	2	2.5	2	2.5	.	.	1	1.3	.	.	4	5.1	72	91.1
		25-29	94	2	2.1	.	.	3	3.2	.	.	1	1.1	2	2.1	90	97.8
		30-34	70	2	2.9	1	1.4	1	1.4	.	.	1	1.4	1	1.4	64	95.5
		35+	43	1	2.3	2	4.7	.	.	38	88.4
	Years since diagnosis	5-9	42	1	2.4	.	.	3	7.1	4	9.5	36	85.7
		10-14	122	3	2.5	1	0.8	4	3.3	5	4.1	116	96.7
		15-19	99	2	2.0	2	2.0	.	.	1	1.0	2	2.0	.	.	93	97.9
		20+	69	1	1.4	.	.	1	1.4	.	.	2	2.9	.	.	60	87.0
	Age at diagnosis	<1	2	1	50.0	1	50.0
		1-4	24	19	82.6
		5-9	86	1	1.2	1	1.2	2	2.3	1	1.2	1	1.2	1	1.2	82	95.3
		10-14	122	5	4.1	1	0.8	4	3.3	.	.	2	1.6	2	1.6	111	93.3
		15-20	98	1	1.0	1	1.0	1	1.0	.	.	1	1.0	6	6.2	92	95.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		685	17	2.5	254	37.3	17	2.5	7	1.0	.	.	7	1.0	1	0.1
	Age at baseline	<18	54	.	.	26	48.1	2	3.8	1	1.9	.	.
		18-19	33	1	3.0	9	27.3	1	3.0	1	3.0
		20-24	157	3	1.9	60	38.5	4	2.6	1	0.6	.	.	4	2.6	.	.
		25-29	193	2	1.0	84	43.8	7	3.6	2	1.0	.	.	1	0.5	.	.
		30-34	153	5	3.3	49	32.5	3	2.0	1	0.7	.	.	1	0.7	.	.
		35+	95	6	6.3	26	27.4	.	.	3	3.2
	Years since diagnosis	5-9	90	4	4.5	29	32.6	2	2.3	1	1.1	.	.	1	1.1	1	1.1
		10-14	231	5	2.2	100	43.3	9	3.9	1	0.4	.	.	4	1.7	.	.
		15-19	214	4	1.9	87	41.2	5	2.3	2	0.9	.	.	2	0.9	.	.
		20+	150	4	2.7	38	25.3	1	0.7	3	2.0
	Age at diagnosis	<1	4	.	.	3	75.0	1	25.0
		1-4	50	.	.	19	38.0	1	2.0	.	.
		5-9	170	1	0.6	61	35.9	4	2.4	1	0.6	.	.	1	0.6	.	.
		10-14	257	1	0.4	99	39.0	9	3.5	4	1.6	.	.	3	1.2	1	0.4
		15-20	204	15	7.4	72	35.5	3	1.5	2	1.0	.	.	2	1.0	.	.
Males	All cases		353	10	2.8	130	36.9	6	1.7	3	0.9	.	.	3	0.9	.	.
	Age at baseline	<18	24	.	.	11	45.8	1	4.3	.	.
		18-19	17	.	.	3	17.6
		20-24	78	1	1.3	28	36.4	1	1.3	1	1.3	.	.
		25-29	99	2	2.0	46	46.5	4	4.0	1	1.0	.	.	1	1.0	.	.
		30-34	83	2	2.4	28	33.7	1	1.2	1	1.2
		35+	52	5	9.6	14	26.9	.	.	1	1.9
	Years since diagnosis	5-9	48	3	6.4	17	36.2	1	2.2	.	.
		10-14	109	1	0.9	44	40.4	3	2.8	2	1.8	.	.
		15-19	115	3	2.6	49	42.6	3	2.6	1	0.9
		20+	81	3	3.7	20	24.7	.	.	2	2.5
	Age at diagnosis	<1	2	.	.	1	50.0
		1-4	26	.	.	10	38.5	1	3.8	.	.
		5-9	84	.	.	27	32.1	1	1.2	1	1.2
		10-14	135	.	.	51	38.1	4	3.0	2	1.5	.	.	1	0.8	.	.
		15-20	106	10	9.4	41	38.7	1	0.9	1	0.9	.	.
Females	All cases		332	7	2.1	124	37.7	11	3.3	4	1.2	.	.	4	1.2	1	0.3
	Age at baseline	<18	30	.	.	15	50.0	2	6.7
		18-19	16	1	6.3	6	37.5	1	6.3	1	6.3
		20-24	79	2	2.5	32	40.5	3	3.8	1	1.3	.	.	3	3.8	.	.
		25-29	94	.	.	38	40.9	3	3.2	1	1.1
		30-34	70	3	4.3	21	30.9	2	2.9	1	1.4	.	.
		35+	43	1	2.3	12	27.9	.	.	2	4.7
	Years since diagnosis	5-9	42	1	2.4	12	28.6	2	4.8	1	2.4	1	2.4
		10-14	122	4	3.3	56	45.9	6	4.9	1	0.8	.	.	2	1.6	.	.
		15-19	99	1	1.0	38	39.6	2	2.0	1	1.0	.	.	2	2.0	.	.
		20+	69	1	1.4	18	26.1	1	1.4	1	1.4
	Age at diagnosis	<1	2	.	.	2	.	1	50.0
		1-4	24	.	.	9	37.5
		5-9	86	1	1.2	34	39.5	3	3.5	1	1.2	.	.
		10-14	122	1	0.8	48	40.0	5	4.1	2	1.6	.	.	2	1.6	1	0.8
		15-20	98	5	5.2	31	32.0	2	2.1	2	2.1	.	.	1	1.0	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Osteosarcoma

			BCNU (Carmustine)		Busulfan		Carboplatin		CCNU (Lomustine)		Chlorambucil		Cis-Platinum		Cyclophosphamide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	1	0.1	1	0.1	71	6.2	614	54.0	468	41.1
	Age at baseline	<18	25	1	4.0	19	76.0	14	56.0
		18-19	27	3	11.1	19	70.4	14	51.9
		20-24	183	21	11.5	122	67.0	95	51.9
		25-29	317	21	6.6	198	63.3	107	34.2
		30-34	337	15	4.5	167	49.9	119	35.4
		35+	260	1	0.4	1	0.4	10	3.9	89	34.8	119	46.5
	Years since diagnosis	5-9	118	14	12.0	87	74.4	72	61.0
		10-14	361	28	7.8	236	66.3	143	40.1
		15-19	390	.	.	1	0.3	21	5.4	179	46.1	132	34.0
		20+	280	1	0.4	.	.	8	2.9	112	40.4	121	43.7
	Age at diagnosis	1-4	21	16	76.2	9	42.9
		5-9	151	11	7.3	78	51.7	55	36.4
		10-14	491	1	0.2	.	.	32	6.6	283	58.1	203	41.8
		15-20	486	.	.	1	0.2	28	5.8	237	49.5	201	41.7
Males	All cases		577	1	0.2	1	0.2	36	6.3	313	54.7	240	41.9
	Age at baseline	<18	18	1	5.6	13	72.2	9	50.0
		18-19	12	1	8.3	8	66.7	4	33.3
		20-24	86	12	14.0	54	62.8	44	51.2
		25-29	165	10	6.1	108	66.3	56	34.4
		30-34	158	5	3.2	83	53.2	62	39.5
		35+	138	1	0.7	1	0.7	7	5.1	47	34.3	65	47.4
	Years since diagnosis	5-9	64	8	12.5	45	70.3	36	56.3
		10-14	190	13	6.9	124	66.3	78	41.5
		15-19	190	.	.	1	0.5	11	5.8	88	46.6	67	35.4
		20+	133	1	0.8	.	.	4	3.0	56	42.4	59	44.7
	Age at diagnosis	1-4	11	8	72.7	5	45.5
		5-9	76	6	7.9	37	48.7	28	36.8
		10-14	220	1	0.5	.	.	13	5.9	129	58.9	88	40.4
		15-20	270	.	.	1	0.4	17	6.3	139	52.3	119	44.4
Females	All cases		572	35	6.2	301	53.2	228	40.2
	Age at baseline	<18	7	6	85.7	5	71.4
		18-19	15	2	13.3	11	73.3	10	66.7
		20-24	97	9	9.4	68	70.8	51	52.6
		25-29	152	11	7.2	90	60.0	51	34.0
		30-34	179	10	5.6	84	46.9	57	31.8
		35+	122	3	2.5	42	35.3	54	45.4
	Years since diagnosis	5-9	54	6	11.3	42	79.2	36	66.7
		10-14	171	15	8.8	112	66.3	65	38.5
		15-19	200	10	5.0	91	45.7	65	32.7
		20+	147	4	2.8	56	38.6	62	42.8
	Age at diagnosis	1-4	10	8	80.0	4	40.0
		5-9	75	5	6.7	41	54.7	27	36.0
		10-14	271	19	7.1	154	57.5	115	42.9
		15-20	216	11	5.2	98	46.0	82	38.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

Chemotherapy agents - Alkylating agents (including Platinum drugs): Osteosarcoma

			DTIC		Ifosfamide		Melphalan		Nitrogen Mustard		Procarbazine		ThioTepa		Temozolomide		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	24	2.1	296	25.9	47	4.1	1	0.1	.	.
	Age at baseline	<18	25	.	.	8	32.0
		18-19	27	.	.	8	29.6
		20-24	183	4	2.2	60	33.1	3	1.6
		25-29	317	7	2.2	87	27.5	3	0.9
		30-34	337	9	2.7	87	25.9	18	5.4
		35+	260	4	1.6	46	18.0	23	9.0	1	0.4	.	.
	Years since diagnosis	5-9	118	6	5.1	38	32.5	1	0.8
		10-14	361	10	2.8	90	25.1	2	0.6
		15-19	390	5	1.3	108	27.8	20	5.2	1	0.3	.	.
		20+	280	3	1.1	60	21.7	24	8.7
	Age at diagnosis	1-4	21	.	.	5	23.8
		5-9	151	.	.	50	33.1	7	4.6
		10-14	491	.	.	137	28.1	18	3.7
		15-20	486	24	5.0	104	21.6	22	4.6	1	0.2	.	.
Males	All cases		577	14	2.4	154	26.9	22	3.8	1	0.2	.	.
	Age at baseline	<18	18	.	.	7	38.9
		18-19	12	.	.	4	33.3
		20-24	86	3	3.5	31	36.5	2	2.3
		25-29	165	4	2.5	46	28.0	2	1.2
		30-34	158	5	3.2	40	25.5	7	4.5
		35+	138	2	1.5	26	19.0	11	8.0	1	0.7	.	.
	Years since diagnosis	5-9	64	4	6.3	23	35.9	1	1.6
		10-14	190	6	3.2	42	22.3	1	0.5
		15-19	190	2	1.1	56	29.6	11	5.8	1	0.5	.	.
		20+	133	2	1.5	33	25.0	9	6.8
	Age at diagnosis	1-4	11	.	.	4	36.4
		5-9	76	.	.	26	34.2	3	3.9
		10-14	220	.	.	68	31.2	7	3.2
		15-20	270	14	5.2	56	20.9	12	4.5	1	0.4	.	.
Females	All cases		572	10	1.8	142	25.0	25	4.4
	Age at baseline	<18	7	.	.	1	14.3
		18-19	15	.	.	4	26.7
		20-24	97	1	1.0	29	30.2	1	1.0
		25-29	152	3	2.0	41	27.0	1	0.7
		30-34	179	4	2.2	47	26.3	11	6.1
		35+	122	2	1.7	20	16.8	12	10.1
	Years since diagnosis	5-9	54	2	3.7	15	28.3
		10-14	171	4	2.3	48	28.1	1	0.6
		15-19	200	3	1.5	52	26.1	9	4.5
		20+	147	1	0.7	27	18.6	15	10.3
	Age at diagnosis	1-4	10	.	.	1	10.0
		5-9	75	.	.	24	32.0	4	5.3
		10-14	271	.	.	69	25.6	11	4.1
		15-20	216	10	4.7	48	22.5	10	4.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included